WO2020260577A1 - Oil-in-water emulsion of nano-sized self-emulsified particulates - Google Patents
Oil-in-water emulsion of nano-sized self-emulsified particulates Download PDFInfo
- Publication number
- WO2020260577A1 WO2020260577A1 PCT/EP2020/068018 EP2020068018W WO2020260577A1 WO 2020260577 A1 WO2020260577 A1 WO 2020260577A1 EP 2020068018 W EP2020068018 W EP 2020068018W WO 2020260577 A1 WO2020260577 A1 WO 2020260577A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- water emulsion
- emulsion according
- emulsion
- surfactant
- Prior art date
Links
- 239000007764 o/w emulsion Substances 0.000 title claims abstract description 169
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 55
- 239000000839 emulsion Substances 0.000 claims description 144
- 239000004094 surface-active agent Substances 0.000 claims description 124
- 239000003921 oil Substances 0.000 claims description 107
- 235000019198 oils Nutrition 0.000 claims description 107
- 238000010438 heat treatment Methods 0.000 claims description 71
- 239000004480 active ingredient Substances 0.000 claims description 61
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 51
- -1 paraffins Substances 0.000 claims description 42
- 238000001816 cooling Methods 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 28
- 239000000796 flavoring agent Substances 0.000 claims description 27
- 235000019634 flavors Nutrition 0.000 claims description 27
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims description 20
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 claims description 18
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 18
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 16
- 239000000654 additive Substances 0.000 claims description 16
- 230000000996 additive effect Effects 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 12
- 230000000873 masking effect Effects 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 239000013067 intermediate product Substances 0.000 claims description 11
- 230000003019 stabilising effect Effects 0.000 claims description 11
- 239000007858 starting material Substances 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 229940113164 trimyristin Drugs 0.000 claims description 9
- 229960001947 tripalmitin Drugs 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
- 239000003905 agrochemical Substances 0.000 claims description 8
- 239000000611 antibody drug conjugate Substances 0.000 claims description 8
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 8
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 claims description 8
- 229930182470 glycoside Natural products 0.000 claims description 8
- 150000002338 glycosides Chemical class 0.000 claims description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 8
- 235000021388 linseed oil Nutrition 0.000 claims description 8
- 239000000944 linseed oil Substances 0.000 claims description 8
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 8
- 229940093633 tricaprin Drugs 0.000 claims description 8
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000002417 nutraceutical Substances 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- 239000008158 vegetable oil Substances 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 5
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 125000000129 anionic group Chemical group 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 229960000106 biosimilars Drugs 0.000 claims description 5
- 235000021466 carotenoid Nutrition 0.000 claims description 5
- 150000001747 carotenoids Chemical class 0.000 claims description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 5
- 235000019136 lipoic acid Nutrition 0.000 claims description 5
- 235000012680 lutein Nutrition 0.000 claims description 5
- 229960005375 lutein Drugs 0.000 claims description 5
- 239000001656 lutein Substances 0.000 claims description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 5
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 5
- 235000012661 lycopene Nutrition 0.000 claims description 5
- 229960004999 lycopene Drugs 0.000 claims description 5
- 239000001751 lycopene Substances 0.000 claims description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 229940068065 phytosterols Drugs 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 150000008163 sugars Chemical class 0.000 claims description 5
- 229960002663 thioctic acid Drugs 0.000 claims description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 239000000341 volatile oil Substances 0.000 claims description 5
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 4
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 4
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 claims description 4
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 claims description 4
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 4
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 4
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 claims description 4
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 4
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- MEESPVWIOBCLJW-KTKRTIGZSA-N [(z)-octadec-9-enyl] dihydrogen phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOP(O)(O)=O MEESPVWIOBCLJW-KTKRTIGZSA-N 0.000 claims description 4
- GYGAZRPDUOHMAF-UHFFFAOYSA-N acetic acid elaidylester Natural products CCCCCCCCC=CCCCCCCCCOC(C)=O GYGAZRPDUOHMAF-UHFFFAOYSA-N 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- 150000005215 alkyl ethers Chemical class 0.000 claims description 4
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 235000019568 aromas Nutrition 0.000 claims description 4
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 4
- 229960000074 biopharmaceutical Drugs 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000005487 catechin Nutrition 0.000 claims description 4
- 239000003093 cationic surfactant Substances 0.000 claims description 4
- 229950001002 cianidanol Drugs 0.000 claims description 4
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 4
- 239000000562 conjugate Substances 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 229930182497 flavan-3-ol Natural products 0.000 claims description 4
- 150000002206 flavan-3-ols Chemical class 0.000 claims description 4
- 229930003949 flavanone Natural products 0.000 claims description 4
- 150000002208 flavanones Chemical class 0.000 claims description 4
- 235000011981 flavanones Nutrition 0.000 claims description 4
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims description 4
- 150000002216 flavonol derivatives Chemical class 0.000 claims description 4
- 235000011957 flavonols Nutrition 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 4
- 229940025878 hesperidin Drugs 0.000 claims description 4
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 4
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 4
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 4
- 235000008696 isoflavones Nutrition 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 229940107604 lutein esters Drugs 0.000 claims description 4
- 150000002658 luteins Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 229940074096 monoolein Drugs 0.000 claims description 4
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002114 octoxynol-9 Polymers 0.000 claims description 4
- 229940060184 oil ingredients Drugs 0.000 claims description 4
- GYGAZRPDUOHMAF-KHPPLWFESA-N oleyl acetate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(C)=O GYGAZRPDUOHMAF-KHPPLWFESA-N 0.000 claims description 4
- 239000006014 omega-3 oil Substances 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 claims description 4
- 229920002414 procyanidin Polymers 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000035807 sensation Effects 0.000 claims description 4
- 235000019615 sensations Nutrition 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims description 4
- 229930003802 tocotrienol Natural products 0.000 claims description 4
- 239000011731 tocotrienol Substances 0.000 claims description 4
- 235000019148 tocotrienols Nutrition 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N zeaxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000007515 enzymatic degradation Effects 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 239000008180 pharmaceutical surfactant Substances 0.000 claims description 3
- 230000001953 sensory effect Effects 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229930182558 Sterol Chemical class 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 150000003505 terpenes Chemical class 0.000 claims 1
- 235000007586 terpenes Nutrition 0.000 claims 1
- 229940045999 vitamin b 12 Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 6
- 238000002844 melting Methods 0.000 description 47
- 230000008018 melting Effects 0.000 description 46
- 238000007710 freezing Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000004945 emulsification Methods 0.000 description 13
- 230000008014 freezing Effects 0.000 description 13
- 235000013305 food Nutrition 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 8
- 239000007908 nanoemulsion Substances 0.000 description 8
- 239000000470 constituent Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- 235000013310 margarine Nutrition 0.000 description 4
- 239000003264 margarine Substances 0.000 description 4
- 239000008268 mayonnaise Substances 0.000 description 4
- 235000010746 mayonnaise Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930003779 Vitamin B12 Natural products 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 235000019163 vitamin B12 Nutrition 0.000 description 3
- 239000011715 vitamin B12 Substances 0.000 description 3
- 235000019489 Almond oil Nutrition 0.000 description 2
- 244000205479 Bertholletia excelsa Species 0.000 description 2
- 235000012284 Bertholletia excelsa Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 235000019487 Hazelnut oil Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102100030694 Interleukin-11 Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 235000019774 Rice Bran oil Nutrition 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 235000021302 avocado oil Nutrition 0.000 description 2
- 239000008163 avocado oil Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229960005084 calcitriol Drugs 0.000 description 2
- 235000020964 calcitriol Nutrition 0.000 description 2
- 239000011612 calcitriol Substances 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 239000008169 grapeseed oil Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010468 hazelnut oil Substances 0.000 description 2
- 239000010460 hemp oil Substances 0.000 description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 2
- 229960001587 hesperetin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical group CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- 229960001840 oprelvekin Drugs 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 239000008165 rice bran oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- XGQXULJHBWKUJY-LYIKAWCPSA-N (z)-but-2-enedioic acid;n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C XGQXULJHBWKUJY-LYIKAWCPSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- UIKWDDSLMBHIFT-UVHMKAGCSA-N 2-[4-[(3e)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethyl decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CC\C=C/1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2\1 UIKWDDSLMBHIFT-UVHMKAGCSA-N 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- ZGDLVKWIZHHWIR-UHFFFAOYSA-N 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2CCOCC2)N=C1 ZGDLVKWIZHHWIR-UHFFFAOYSA-N 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 description 1
- JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- CCOAINFUFGBHBA-UETGHTDLSA-N Oxantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CC(O)=C1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 CCOAINFUFGBHBA-UETGHTDLSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- AQXXZDYPVDOQEE-MXDQRGINSA-N Pyrantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 AQXXZDYPVDOQEE-MXDQRGINSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002054 acenocoumarol Drugs 0.000 description 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229960000919 alatrofloxacin Drugs 0.000 description 1
- UUZPPAMZDFLUHD-VUJLHGSVSA-N alatrofloxacin Chemical compound C([C@@H]1[C@H]([C@@H]1C1)NC(=O)[C@H](C)NC(=O)[C@@H](N)C)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F UUZPPAMZDFLUHD-VUJLHGSVSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 229960004685 aloxiprin Drugs 0.000 description 1
- MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 238000005311 autocorrelation function Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229950003588 axetil Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 229950001957 bentazepam Drugs 0.000 description 1
- AIZFEOPQVZBNGH-UHFFFAOYSA-N bentazepam Chemical compound C1=2C=3CCCCC=3SC=2NC(=O)CN=C1C1=CC=CC=C1 AIZFEOPQVZBNGH-UHFFFAOYSA-N 0.000 description 1
- PMPQCPQAHTXCDK-UHFFFAOYSA-M benzyl-dimethyl-(2-phenoxyethyl)azanium;3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1.C=1C=CC=CC=1C[N+](C)(C)CCOC1=CC=CC=C1 PMPQCPQAHTXCDK-UHFFFAOYSA-M 0.000 description 1
- 229960000254 bephenium Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 229960004037 bromperidol Drugs 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960003874 butobarbital Drugs 0.000 description 1
- STDBAQMTJLUMFW-UHFFFAOYSA-N butobarbital Chemical compound CCCCC1(CC)C(=O)NC(=O)NC1=O STDBAQMTJLUMFW-UHFFFAOYSA-N 0.000 description 1
- 229960002120 butoconazole nitrate Drugs 0.000 description 1
- ZHPWRQIPPNZNML-UHFFFAOYSA-N butoconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 ZHPWRQIPPNZNML-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 229960003475 cambendazole Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
- 229960001704 carbimazole Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960001658 carbromal Drugs 0.000 description 1
- OPNPQXLQERQBBV-UHFFFAOYSA-N carbromal Chemical compound CCC(Br)(CC)C(=O)NC(N)=O OPNPQXLQERQBBV-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960001552 chlorprothixene Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003622 clotiazepam Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229950009702 darodipine Drugs 0.000 description 1
- QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 229960003887 dichlorophen Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 229960000465 dihydrotachysterol Drugs 0.000 description 1
- ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960003645 econazole nitrate Drugs 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 1
- 229960000972 enoximone Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 229960002209 ethinamate Drugs 0.000 description 1
- GXRZIMHKGDIBEW-UHFFFAOYSA-N ethinamate Chemical compound NC(=O)OC1(C#C)CCCCC1 GXRZIMHKGDIBEW-UHFFFAOYSA-N 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960005473 fenbendazole Drugs 0.000 description 1
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
- 229960002724 fenoldopam Drugs 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229960003973 fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229940042988 flupenthixol decanoate Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- LZLGHWHSUZVUFZ-HZPDHXFCSA-N folerogenin Chemical compound C1([C@@H]2[C@H](O)C(=O)C3=C(O)C=C(C=C3O2)OC)=CC=C(O)C=C1 LZLGHWHSUZVUFZ-HZPDHXFCSA-N 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 229960003050 guanabenz acetate Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 229960003911 histrelin acetate Drugs 0.000 description 1
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960002614 lanatoside c Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
- 229960000365 meptazinol Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960003746 metildigoxin Drugs 0.000 description 1
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical compound O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- XCGYUJZMCCFSRP-UHFFFAOYSA-N oxamniquine Chemical compound OCC1=C([N+]([O-])=O)C=C2NC(CNC(C)C)CCC2=C1 XCGYUJZMCCFSRP-UHFFFAOYSA-N 0.000 description 1
- 229960000462 oxamniquine Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 description 1
- 229960004454 oxfendazole Drugs 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960002404 palifermin Drugs 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 108010027841 pegademase bovine Proteins 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960000280 phenindione Drugs 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- BUFJIHPUGZHTHL-NKFFZRIASA-N phyllohydroquinone Chemical compound C1=CC=CC2=C(O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(O)=C21 BUFJIHPUGZHTHL-NKFFZRIASA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001778 rabeprazole sodium Drugs 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000000235 small-angle X-ray scattering Methods 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960004718 sulconazole nitrate Drugs 0.000 description 1
- PBCZLFBEBARBBI-UHFFFAOYSA-N sulfabenzamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC(=O)C1=CC=CC=C1 PBCZLFBEBARBBI-UHFFFAOYSA-N 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000005320 surfactant adsorption Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229940099419 targretin Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
Definitions
- the present invention is directed to an oil-in-water emulsion and methods in which the oil droplets exhibit self-emulsified particulates of a nano-sized diameter and within a narrow size range for used to deliver or store ingredients and provide a new or improved functionality.
- Oil-in-water emulsions are widely used in food, cosmetic, agrochemical, zootechnical and pharma industries. Such emulsions can be exploited for many different purposes or applications such as delivering ingredients, or creating a certain feel, texture, fragrance or sensation as well as taste or smoothness.
- emulsions also deliver active compounds, such as, flavours, vitamins, antioxidants, nutraceuticals, phytochemicals, drugs, chemicals, enzymes, antibodies, peptibodies, vaccines, viral vectors, hormone therapies, gene-editing techniques, biosimilars and others.
- Administering active components requires the use of an appropriate vehicle for bringing an effective amount of the active component into a desired place of action.
- Oil-in-water emulsions are commonly used as delivery systems since they take advantage of the solubility of lipophilic compounds in the oil.
- Dissolution of active compounds, such as phytosterols, carotenoids or water- insoluble drugs into the oil droplets of emulsions or dispersions not only aids dispersibility (homogeneous incorporation of the active elements), but can also increase their bioavailability.
- Clinical and animal experiments have demonstrated better efficacy and bioavailability of active compounds, such as drugs and nutrients, when the active compounds are dissolved or solubilised, for instance into nano-emulsions or nano-dispersions.
- triglyceride-based emulsions or dispersions such as triglyceride nano-emulsions or nano-dispersions as an alternative to other oils in different industrial applications.
- triglyceride nano-emulsions or nano-dispersions are, however, usually obtained via high-pressure homogenization (HPH) or by ultra-sonication (known as high-energy methods) and the typical drop size is in the range of 150 to 300 nm [1-3]
- an oil-in-water emulsion comprising particulates with a diameter range of between about 10 nm to about 500 nm.
- oil-in-water emulsion wherein oil droplets of a diameter greater than 1 pm exhibit nano-sized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm, due to the presence of:
- an oil-in-water emulsion wherein the oil-inwater emulsion comprises an active ingredient.
- an oil-in-water emulsion wherein the active ingredient is lipophilic is provided.
- an oil-in-water emulsion wherein the active ingredient is between 0.0001% and 50% of the total weight of the emulsion.
- an oil-in-water emulsion wherein the emulsion comprises disseminated oil droplets having nano-sized self-emulsified particulates comprising: i) oil selected from the group consisting of triglyceride oil, vegetable oil, essential oil, flavouring oil, esters and mixtures thereof;
- HLB ⁇ lipophilic surfactant
- HLB ⁇ hydrophilic surfactant
- an oil-in-water emulsion wherein the oil is selected from the group consisting of vegetable oils, triglyceride oils, essential oils, flavouring oils, esters, alkanes, paraffins, waxes, diglycerides, phospholipids and mixtures thereof.
- an oil-in-water emulsion wherein the oil is triglyceride oil.
- an oil-in-water emulsion wherein the triglyceride oil is selected from the group consisting of tricaprin (CioTG), trilaurin (C12TG), trimyristin (C14TG), tripalmitin (C16TG) and tristearin (CisTG) or mixtures thereof.
- an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is between about 0.01% and about 20%, between about 0.01% and about 10%, between about 0.01% and about 5%, between about 0.025% and about 1.9%, between about 0.05% and about 1.8%, between about 0.1% and about 1.5%, between about 0.15% and about 1.25%, between about 0.2% and about 1%, between about 0.4% and about 0.8% of the total weight of the emulsion, and wherein the concentration of the hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion.
- an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is 0.7%. In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is 2.9%.
- an oil-in-water emulsion wherein for 1% oil content in the emulsion the preferred concentration of the lipophilic surfactant is between about 0.01% and about 3%, between about 0.025% and about 2.8%, between about 0.05% and about 2.6%, between about 0.1% and about 2.4%, between about 0.2% and about 2%, between about 0.4% and about 2%, between about 0.8% and about 1.8% of the total weight of the emulsion, and wherein the concentration of the hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion.
- an oil-in-water emulsion wherein for 1% oil content in the emulsion the preferred concentration of the lipophilic surfactant is between about 0.8% and about 1.8% of the total weight of the emulsion.
- an oil-in-water emulsion wherein for 1% oil content in the emulsion the preferred concentration of lipophilic surfactant is about 1.5% of the weight of the total emulsion and the concentration of the hydrophilic surfactant is about 1% of the weight of the total emulsion.
- c is the minimal needed surfactant concentration
- f is the oil volume fraction
- G is the monolayer surfactant adsorption
- d 32 is the mean volume-surface diameter of the droplets in the produced emulsion
- the concentration of the lipophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
- the concentration of the hydrophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
- an oil-in-water emulsion wherein the lipophilic surfactant is at least one lipophilic surfactant selected from the group consisting of sorbitan monoalkylate (C n Sorb) where n is between 12 and 18; polyoxyethylene glycol hexadecyl ether (C 16 EO 2 ), polyoxyethylene glycol stearyl ether (CisEC ), polyethylene glycol monooleyl (Ci 8:i E0 2 ), oleyl phosphate, oleyl acetate and 1-oleoyl-rac-glycerol (monoolein), glucoside-based surfactants, diglyceride surfactants, phospholipid surfactants, as well as surfactants that are not only used for stabilization only but where the surfactant is also an active ingredient itself.
- C n Sorb sorbitan monoalkylate
- an oil-in-water emulsion wherein the hydrophilic surfactant is at least one hydrophilic surfactant selected from the group consisting of: nonionic polyoxyethylene alkyl ether (C IntelEO w ), polyoxyethylene sorbitan monoalkylate (C n SorbEO m ) where n is between 12 and 40 and where m is between 20 and 50; polyethylene glycol monooleyl ether (Ci 8:i EO m ) where m is between 7 and 20; polyoxyethylene octyl phenyl ether; anionic sodium dodecyl sulfate (SDS); sodium lauryl ether sulfate (SLES); cationic surfactant cetyltrimethyl ammonium bromide (CTAB); and cocamidopropyl betaine (CAPB), glucoside- based surfactants (such as alkyl polyglycosides, glycopeptides and esters), peptide
- CNU w nonionic
- an oil-in-water emulsion wherein the emulsion is exposed to at least two cooling-heating cycles, at least three cooling-heating cycles, at least four cooling-heating cycles, at least five cooling-heating cycles, at least six cooling-heating cycles, at least seven cooling-heating cycles, at least eight cooling-heating cycles or more cooling-heating cycles.
- the heating temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the melting temperature of the oil.
- the cooling temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the oil.
- the heating temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the melting temperature of the triglyceride.
- the cooling temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the triglyceride.
- an oil-in-water emulsion wherein the nanosized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised with at least one lipophilic surfactant and at least one hydrophilic surfactant.
- an emulsion comprising stabilised nano-sized self-emulsified particulates have a diameter of between about 12 nm to about 480 nm, about 14 nm to about 460 nm, about 16 nm to about 440 nm, about 18 rnn to about 420 nm, about 20 nm to about 400 ran, about 22 nm to about 380 nm, about 24 nm to about 360 nm, about 26 nm to about 340 nm, about 28 nm to about 320 nm, 30 nm to about 300nm, about 35 nm to about 280 nm, about 40 nm of about 260nm, about 45 nm to about 240 nm, about 50 nm to about 220, about 55 nm to about 200, about 60 nm to about 180 nm, about 65 nm to about 160 nm, about 70 nm to about 140 nm, about 75 n
- an oil-in-water emulsion wherein over 70% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 75% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 80% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm.
- an oil-in-water emulsion wherein over 85% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 90% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 95% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm.
- an oil-in-water emulsion wherein over 96% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 97% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 98% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 99% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm.
- an oil-in-water emulsion wherein the nanosized self-emulsified particulates exhibit a diameter of about 20 nm to about 50 nm.
- an oil-in-water emulsion wherein over 70% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 75% of the nano-sized self- emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 80% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm.
- an oil-in-water emulsion wherein over 85% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 90% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 95% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm.
- an oil-in-water emulsion wherein over 96% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 97% of the nano-sized self- emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 98% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm.
- an oil-in-water emulsion wherein over 99% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments, there is provided an oil-in-water emulsion wherein the nano-sized self-emulsified particulates exhibit a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 70% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm.
- an oil-in-water emulsion wherein over 75% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 80% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 85% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm.
- an oil-in-water emulsion wherein over 90% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 95% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 96% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm.
- an oil-in-water emulsion wherein over 97% of the nano-sized self- emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 98% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 99% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm.
- an oil-in-water emulsion wherein the nanosized self-emulsified particulates exhibit a diameter of about 20 nm.
- an oil-in-water emulsion wherein over 70% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm. In some embodiments, there is provided an oil-in-water emulsion wherein over 75% or more of the nanosized self-emulsified particulates exhibit a diameter of about 20 nm. In some embodiments, there is provided an oil-in-water emulsion wherein over 80% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm.
- an oil-inwater emulsion wherein over 85% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm. In some embodiments, there is provided an oil-in-water emulsion wherein over 90% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm. In some embodiments, there is provided an oil-in-water emulsion wherein over 95% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm.
- an oil-in-water emulsion wherein the concentration of the stabilising lipophilic surfactant is between about 0.01% and about 20%, between about 0.01% and about 10%, between about 0.01% and about 5%, between about 0.01% and about 2%, between about 0.025% and about 1.9%, between about 0.05% and about 1.8%, between about 0.1 % and about 1.5%, between about 0.15% and about 1.25%, between about 0.2% and about 1%, between about 0.4% and about 0.8% of the total weight of the emulsion, and wherein the concentration of the stabilising hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion.
- the concentration of the stabilising lipophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
- the concentration of the stabilising hydrophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
- an oil-in-water emulsion wherein the cooling rate of the cooling-heating cycle is between about 0.01 K min 1 and about 1000 K min 1 , between about 0.025 K min 1 and about 50 K min 1 , between about 0.05 K min 1 and about 40 K min 1 , between about 0.075 K min 1 and about 35 K min 1 , between about 0.1 K min 1 and about 30 K min 1 , between about 0.125 K min 1 and about 25 K min 1 , between about 0.2 K min 1 and about 20 K min 1 , between about 0.4 K min 1 and about 15 K min 1 , between about 0.5 K min 1 and about 10 K min 1 , between about 0.75 K min 1 and about 7.5 K min 1 , between about 1 K min 1 and about 5 K min 1 , between about 1.25 K min 1 and about 2.5 K min 1 , between about 1.5 K min 1 and about 2 K min 1 .
- the cooling rate is about 1 K min 1 .
- an oil-in-water emulsion wherein the self- emulsification can happen in the frozen state without heating, or where the heating rate of the cooling-heating cycle is between about 0.01 K min 1 and about 1000 K min 1 .
- an oil-in-water emulsion wherein self- emulsification occurs at between about 33°C and about 37°C.
- an oil-in-water emulsion wherein self- emulsification occurs at about 35°C.
- the triglyceride is at least one selected from the group consisting of trimyristine, trilaurine, tristearine and tripalmitine.
- an oil-in-water emulsion wherein the active ingredient is at least one selected from the group consisting of flavours, flavour precursors, aromas, aroma precursors, taste enhancers, salts, sugars, amino-acids, polysaccharides, enzymes, peptides, proteins or carbohydrates, food supplements, food additives, hormones, bacteria, plant extracts, medicaments, drugs, pharmaceuticals, bio-pharmaceutical, biosimilars, vaccines, antigens, antibodies (Abs), peptibodies, antibody-drug-conjugates (ADCs), nutrients, chemicals for agrochemical or cosmetic applications, carotenoids, vitamins, antioxidants or nutraceuticals selected from the group comprising of lutein, lutein esters, [beta] -carotene, tocopherol, tocopherol acetate, tocotrienol, lycopene, Co-QlO, flax seed oil, fish oil, omega-3 oils, omega-6 oils,
- the present emulsions are suitable for use in the food industry such as ice-cream sector, mayonnaise sector or margarine sector.
- an oil-in-water emulsion for used in the food industry.
- an oil-in-water emulsion for use in making an ice-cream product.
- an oil-in-water emulsion for use in making mayonnaise.
- an oil-in-water emulsion for use in making margarine.
- an oil-in-water emulsion wherein the emulsion is dried in a powder form.
- an oil-in-water emulsion wherein the emulsion is a starting material, an intermediate product or an additive to a final product.
- an oil-in-water emulsion wherein the starting material, the intermediate product or additive to a final product is a pharmaceutical, agro-chemical, consumer, food supplement or cosmetic starting material, the intermediate product or additive to a final product.
- an oil-in-water emulsion wherein the starting material, the intermediate product or additive to a final product has an increased shelf-life.
- an oil-in-water emulsion for use in enhancing stability, protection against chemical or enzymatic degradation or oxidation of an active ingredient in the oil-in-water emulsion.
- an oil-in-water emulsion for use in enhancing bioavailability, bioaccessibility or absorption of active ingredient during digestion.
- an oil-in-water emulsion for use in controlled release, burst release, or sustained release of an active ingredient during consumption or digestion.
- an oil-in-water emulsion for use in controlled release of aroma or flavour, burst release of aroma or flavour, or sustained release of aroma or flavour to create new or improved sensory or taste properties.
- an oil-in-water emulsion for use in creating different taste, different texture, mouth feel, mouth coating, or creaminess sensation.
- an oil-in-water emulsion for use in taste masking, off taste masking, flavour masking, off flavour masking, taste modulation or flavour modulation.
- the melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C above the melting temperature of the oil.
- the freezing temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the oil.
- a method for producing an oil-in-water emulsion comprising the steps of: a. preparing an initial emulsion of a lipophilic phase in a hydrophilic phase to form oil droplets of a diameter greater than 1 pm in the presence of at least one lipophilic surfactant and/or at least one hydrophilic surfactant; and
- the initial emulsion comprises an intermediate metastable phase.
- the initial emulsion is subjected to at least one fast cooling cycle.
- the oil is selected from the group consisting of vegetable oils, triglyceride oils, essential oils, flavouring oils, esters, alkanes, paraffins, waxes, diglycerides, phospholipids and mixtures thereof.
- the oil is triglyceride oil.
- the method requires a combination of hydrophilic surfactants and lipophilic surfactants and controlled variation of the emulsion temperature around the cooling-heating or melting-freezing temperature of the triglyceride.
- the initial emulsion is treated by at least two cooling-heating cycles, at least three cooling-heating cycles, at least four cooling-heating cycles, at least five cooling-heating cycles, at least six cooling-heating cycles, at least seven cooling-heating cycles, at least eight cooling-heating cycles or more cooling-heating cycles.
- the heating temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the melting temperature of the triglyceride.
- the cooling temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the triglyceride.
- the nano-sized self- emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised.
- the stabilised nano-sized self- emulsified particulates have a diameter of between about 12 nm to about 480 nm, about 14 nm to about 460 nm, about 16 nm to about 440 nm, about 18 nm to about 420 nm, about 20 nm to about 400 nm, about 22 nm to about 380 nm, about 24 nm to about 360 nm, about 26 nm to about 340 nm, about 28 nm to about 320 nm, 30 nm to about 300nm, about 35 nm to about 280 nm, about 40 nm of about 260nm, about 45 nm to about 240 nm, about 50 nm to
- the cooling rate is between about 0.01 K min 1 and about 1000 K min 1 , between about 0.01 K min 1 and about 50 K min 1 , between about 0.025 K min 1 and about 45 K min 1 , between about 0.05 K min 1 and about 40 K min 1 , between about 0.075 K min 1 and about 35 K min 1 , between about 0.1 K min 1 and about 30 K min 1 , between about 0.125 K min 1 and about 25 K min 1 , between about 0.2 K min 1 and about 20 K min 1 , between about 0.4 K min 1 and about 15 K min 1 , between about 0.5 K min 1 and about 10 K min 1 , between about 0.75 K min 1 and about 7.5 K min 1 , between about 1 K min 1 and about 5 K min 1 , between about 1.25 K min 1 and about 2.5 K min 1 , between about 1.5 K min 1 and about 2 K min 1 .
- the cooling rate is about 1 K min 1 .
- the heating rate is between about 0.01 K min 1 and about 10 K min 1 , between about 0.025 K min 1 and about 9.5 K min 1 , between about 0.05 K min 1 and about 9 K min 1 , between about 0.075 K min 1 and about 8.5 K min 1 , between about 0.1 K min 1 and about 8 K min 1 , between about 0.125 K min 1 and about 7.5 K min 1 , between about 0.2 K min 1 and about 7 K min 1 , between about 0.4 K min 1 and about 6.5 K min 1 , between about 0.5 K min 1 and about 6 K min 1 , between about 0.75 K min 1 and about 5.5 K min 1 , between about 1 K min 1 and about 5 K min 1 , between about 1.25 K min 1 and about 4.5 K min 1 , between about 1.5 K min 1 and about 4 K min 1 , between about 2 K min 1 and about 3 K min 1 .
- the heating rate of the cooling-heating cycle is about 1 K min 1
- FIG 1 Illustrates the drop or droplet size decrease observed with large scale or bulk emulsions - FIG 1(a) and FIG 1(b).
- FIG 2 Depicts the particle disintegration observed upon storage of the emulsion.
- a surfactant or“a triglyceride” includes a single surfactant or triglyceride as well as a plurality of surfactants or triglycerides, including mixtures thereof.
- the term “comprising” means including, made up of, composed of encompass, consist of, constitute and incorporate.
- the term "about” includes the recited number or number and +/- 10% from the recited numeral or number. By way of non-limiting example, the term “about ten (10)” would encompass nine (9) to eleven (11) or 9-11.
- self-emulsification refers to a reduction of size or diameter of oil droplets or drop as a result of temperature changes without physical or mechanically induced agitation or disruption of the drops.
- selfemulsification can be attained by cooling and/or heating the drops.
- self-emulsification of oil droplets of a diameter greater than 1 pm can undergo a reduction in the size or diameter, in the range of between about 10 nm to about 500 nm without physically or mechanically induced agitation or disruption of the droplets.
- the temperature could be set stationary (e.g. with cooling the droplets at a substantially fixed or constant temperature - Example 2).
- self-emulsification can occur without heating and/or cooling cycle.
- an oil-in-water emulsion wherein self-emulsification occurs at constant temperature.
- an oil-in-water emulsion wherein self-emulsification occurs at between about 33°C and about 37°C.
- an oil-in-water emulsion wherein self-emulsification occurs at about 35°C.
- the terms“drop” or“droplet” are used interchangeably unless stated otherwise or the context dictates otherwise.
- “size” is measured on a volumetric-averaged basis, unless otherwise specified.
- The“particulate” or“droplet” in the present invention is a concept, unless otherwise specified, which can encompass not only a particulate or droplet but a particulate or droplet emulsion composed or comprising of agglomeration of such particulates or droplets.
- the size is measured using any method know in the art which is suitable for the particular purpose.
- the size of the droplets for example in the case of micro-size dimensions, is determined using optical microscopy [5]
- the size of the particulates for example in the case of nano-size dimentions, is determined using dynamic light scattering (DLS) by statistically corelating the Brownian motion fluctuations of the particulates [6]
- DLS dynamic light scattering
- the term“exhibit” refers to self-emulsified emulsion which displays or incorporates nano-sized particulates of diameter in the range of about 10 nm to about 500 nm.
- the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 1000 Celsius degrees per minute, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 2000 Celsius degrees per minute (°C/min), or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 3000 °C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 4000 °C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g.
- the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 6000°C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 8000 °C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 9000 °C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 10000 °C/min.
- lipophilic surfactant refers to surfactants which are soluble in lipids or oils.
- lipophilic surfactants include sorbitan monoalkylates (C n Sorb) with n varied between 12 and 18, polyoxyethylene glycol hexadecyl ether (C16EO2), polyoxyethylene glycol stearyl ether (CisEC ), polyethylene glycol monooleyl ether with 2 ethoxy units (CisuECh), oleyl phosphate, oleyl acetate and 1 -oleoyl-rac-glycerol (monoolein).
- surfactants with HLBdO are oil soluble or lipophilic (see Table 2 and Examples).
- nonionic hydrophilic surfactants refers to water-soluble nonionic, anionic, cationic or zwitterionic surfactants.
- nonionic hydrophilic surfactants includes, polyoxyethylene alkyl ethers (C IntelEO w ) and polyoxyethylene sorbitan monoalkylates (C n SorbEO m ) where n can be any one of between 12 and 40, and where m can be any one of between 20 and 50, polyethylene glycol monooleyl ethers (Ci 8:i EO m ) where m can be any one of between 7 and 20, and polyoxyethylene octyl phenyl ether (trade name Triton X100); anionic hydrophilic surfactants include sodium dodecyl sulfate (SDS) and sodium lauryl ether sulfate (SLES); cationic hydrophilic surfactants include cetyltrimethyl ammonium bromide (CTAB
- the at least one lipophilic surfactant and the at least one hydrophilic surfactant have a resulting HLB value (Hydrophilic-Lipophilic Balance) of less ( ⁇ ) than any one of 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4 or less.
- HLB value Hydrophilic-Lipophilic Balance
- the at least one lipophilic surfactant HLB value (Hydrophilic- Lipophilic Balance) ⁇ 10
- the at least one hydrophilic surfactant HLB value is (greater or equal to) > 10.
- the term“active ingredient” refers to at least one ingredient selected from but are not limited to, lipophilic active compounds or a salt, isomer, ester, ether or other derivative thereof selected from: a) acetylcholinesterase inhibitors; b) analgesics and nonsteroidal antiinflammatory agents (NS ALA) selected from aloxiprin, auranofin, azapropazone, benorylate, capsaicin, celecoxib, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen calcium, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, leflunomide, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, rofe
- NS ALA nonsteroidal anti
- the at least one active ingredient is selected from the group consisting of flavours, flavour precursors, aromas, aroma precursors, taste enhancers, beeswax, salts, sugars, amino-acids, polysaccharides, enzymes, peptides, proteins or carbohydrates, food supplements, food additives, hormones, bacteria, plant extracts, medicaments, drugs, pharmaceuticals, bio-pharmaceutical, biosimilars, vaccines, viral vectors, antigens, antibodies (Abs), peptibodies, antibody-drug-conjugates (ADCs), nutrients, chemicals for agro-chemical or cosmetic applications, carotenoids, vitamins, antioxidants or nutraceuticals selected from the group comprising of lutein, lutein esters, [beta] -carotene, tocopherol, tocopherol acetate, tocotrienol, lycopene, Co-QlO, flax seed oil, fish oil, omega-3 oils, omega-6 oils, DHA,
- the present emulsions are suitable for use in the food industry such as ice-cream sector, mayonnaise sector or margarine sector.
- the term“food industry” includes but is not limited to nutritional, functional and nutraceutical foods. Those of skill in the art would be familiar with the particular food industry requirements and be able to adapt the technical teachings of the present oil-in-water emulsions and methods as needed for the industry.
- the oil-in-water emulsion comprises food acceptable excipients, additives or ingredients.
- an oil-in-water emulsion for used in the food industry.
- an oil-in-water emulsion for use in making an ice-cream product.
- an oil-in-water emulsion for use in making mayonnaise.
- an oil-in-water emulsion for use in making margarine.
- an oil-in-water emulsion for use in functional foods such as probiotics, pre-biotics and nutraceuticals.
- the amount of the active ingredient is higher than 0.00001% of the total weight of the emulsion. Preferably it is higher than 0.00003%, more preferably higher than 0.0001%, and even more preferably higher than 0.001% of the total weight of the emulsion.
- the amount of the active ingredient is comprised between 0.00001 and 50 % of the total weight of the emulsion. It is also possible to have an amount of active ingredient comprised between 0.00001 and 40 %.
- the amount of the active ingredient is lower than 50% of the total weight of the emulsion.
- the amount of active ingredient is lower than 40% of the total weight of the emulsion.
- the amount of active ingredient is lower than 30% of the total weight of the emulsion.
- the amount of active ingredient is lower than 20% of the total weight of the emulsion.
- the amount of active ingredient is lower than 10% of the total weight of the emulsion.
- the amount of active ingredient is lower than 5% of the total weight of the emulsion.
- the amount of active ingredient is lower than 2.5% of the total weight of the emulsion.
- the amount of active ingredient is lower than 2% of the total weight of the emulsion.
- the amount of active ingredient is lower than 1% of the total weight of the emulsion. Any combination of the lower and upper range is comprised in the scope of the present invention.
- the amount of the active ingredient can be given in wt% or mol% of the total weight or molarity of the emulsion or the total volume of the emulsion.
- the amount of active ingredient is 10% of the total weight of the emulsion.
- the amount of active ingredient is 7.5% of the total weight of the emulsion.
- the amount of active ingredient is 5% of the total weight of the emulsion.
- the amount of active ingredient is 2.5% of the total weight of the emulsion.
- the amount of active ingredient is 1% of the total weight of the emulsion.
- the term“emulsion” refers to the sum of masses of the hydrophilic phase (e.g. water), the lipophilic phase (e.g. oil or triglyceride) and where stated ingredients dissolved therein.
- the substance used for formation of the particles is liquid at room temperature.
- the substance used for formation of the particles is solid at room temperature.
- room temperature means a comfortable ambient temperature, generally taken as between about 20°C and 25°C (between about 68 and 77°F) with excursions between 10 and 30°C (between about 59 and 86°F) being contemplate, provided the mean kinetic temperature does not exceed 25°C (77°F).
- triglyceride oil or“triglyceride” refers to esters in which three molecules of one or more different fatty acids are linked to a glycerol. They are named according to the fatty acid components; e.g., tristearin contains three molecules of stearic acid, and oleodistearin, one of oleic acid and two of stearic acid.
- triglycerides include at least one of tricaprin (CioTG), trilaurin (CnTG), trimyristin (CMTG), tripalmitin (Ci 6 TG) and tristearin (CisTG), esters or mixtures thereof.
- the composition of the present invention comprises at least one of tricaprin (CioTG), trilaurin (CnTG), trimyristin (CMTG), tripalmitin (C16TG) and tristearin (CisTG) or mixtures thereof.
- CioTG tricaprin
- CnTG trilaurin
- CMTG trimyristin
- C16TG tripalmitin
- CisTG tristearin
- different natural occurring mixtures of triglycerides can be used, for example - coconut oil represents mixture of triglycerides with about 47 % lauric chains, 16 % myristic chains, 10 % palmitic chains, 3% stearic chains, 7% caprylic chains, 8% decanoic chains, 7 % oleic chains and 2 % linoleic chains.
- triglyceride oil also include cottonseed oil, flaxseed oil, almond oil, safflower oil, palm oil, sunflower oil, avocado oil, soybean oil, com oil, canola oil, grapeseed oil, rapeseed oil, hazelnut oil, linseed oil, brazil nut oil, peanut oil, rice bran oil, hemp seed oil, olive oil, sesame oil, peanut oil, palm kernel oil, cocoabutter, butter, lard, tallow, medium chain triglyceride oil, long chain triglyceride oil.
- Emulsions can be prepared using different known methods.
- hand-shaking of the lipophilic surfactants and the hydrophilic surfactant with the oil component such as triglyceride can form the initial emulsion.
- the preparation of the initial emulsion is mechanically stirred or injected via applied pressure, e.g. via membrane, valve or capillary.
- the initial emulsion consists of oil drops or droplets, dispersed in water in the presence of at lipophilic surfactant and hydrophilic surfactant and could be prepared by any other method, including membrane emulsification, high pressure homogenization, rotor- stator homogenization, stirred vessels, magnetic or non-magnetic stirring devices (see Examples).
- the initial emulsion consists of oil droplets with different shape and size such as with diameter greater than about 0.5 pm, 1 pm, 2 pm, 3 pm, 4 pm, 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, 10 pm, 20 pm, 30 pm, 40 pm, 50 pm or greater.
- the oil droplets in the initial emulsion can be of any shape.
- the initial emulsion consists of oil droplets with specific shape and size such as with diameter greater than about 0.5 pm, 1 pm, 2 pm, 3 pm, 4 pm, 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, 10 pm or greater such as 20 pm, 30 pm, 40 pm, 50 pm or greater.
- the oil droplets in the initial emulsion can be of any shape.
- these active ingredients when preparing emulsions with compounds such as active ingredients, which are solid at room temperature, these active ingredients can be melted prior to the initial emulsion formation and maintained at temperature sufficiently high to avoid liquid-solid status transition during emulsification.
- the temperature is not higher than about 10°C relative to the melting point of the selected oil and surfactants.
- the temperature is not higher than about 10°C relative to the melting point of the selected triglyceride and surfactants. [117] In some embodiments, the temperature is not higher than about 7.5°C relative to the melting point of the selected oil and/or surfactants. In some embodiments, the temperature is not higher than about 7.5°C relative to the melting point of the selected triglyceride and surfactants. In some embodiments, the temperature is not higher than about 5°C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 5°C relative to the melting point of the selected triglyceride and surfactants.
- the temperature is not higher than about 2.5°C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 2.5°C relative to the melting point of the selected triglyceride and surfactants. In some embodiments, the temperature is not higher than about 1°C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 1°C relative to the melting point of the selected triglyceride and surfactants. In some embodiments, the temperature is not higher than about 0.5°C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 0.5°C relative to the melting point of the selected triglyceride and surfactants.
- the temperature is not higher than about 0.1 °C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 0.1 °C relative to the melting point of the selected triglyceride and surfactants.
- the temperature is not higher than about 10°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 10°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 7.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 7.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 2.5°C relative to the melting point of the selected active ingredient.
- the temperature is not higher than about 2.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 1°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 1°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 0.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 0.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 0.1 °C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 0.1°C relative to the melting point of the selected active ingredient.
- an oil-in-water emulsion wherein the triglyceride oil is tricaprin (CioTG). In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is trilaurin (CuTG). In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is trimyristin (C 14 TG). In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is tripalmitin (C 16 TG). In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is tristearin (CisTG).
- an oil-in-water emulsion wherein the triglyceride oil is selected from the group consisting of tricaprin (C 10 TG), trilaurin (CuTG), trimyristin (C14TG), tripalmitin (CieTG) and tristearin (CisTG) or mixtures thereof or mixture of triacylglycerols containing various combinations of CIO, C12, C14, C16 and C18 fatty chains.
- the triglyceride oil is selected from the group consisting of tricaprin (C 10 TG), trilaurin (CuTG), trimyristin (C14TG), tripalmitin (CieTG) and tristearin (CisTG) or mixtures thereof or mixture of triacylglycerols containing various combinations of CIO, C12, C14, C16 and C18 fatty chains.
- an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is between about 0.01% and about 2%, between about 0.025% and about 1.9%, between about 0.05% and about 1.8%, between about 0.1% and about 1.5%, between about 0.15% and about 1.25%, between about 0.2% and about 1%, between about 0.4% and about 0.8% of the total weight of the emulsion, and wherein the concentration of the hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion.
- an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is 0.7%. In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is 2.9%.
- an oil-in-water emulsion wherein the concentration of lipophilic surfactant is about 1.5% of the weight of the total emulsion and the concentration of the hydrophilic surfactant is about 1% of the weight of the total emulsion.
- the concentration of the lipophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
- the concentration of the hydrophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
- an oil-in-water emulsion wherein the lipophilic surfactant is at least one lipophilic surfactant selected from the group consisting of sorbitan monoalkylate (C n Sorb) where n is between 12 and 18; polyoxyethylene glycol hexadecyl ether (C16EO2), polyoxyethylene glycol stearyl ether (CigECh), polyethylene glycol monooleyl (Ci8 :i E02), oleyl phosphate, oleyl acetate and 1-oleoyl-rac-glycerol (monoolein) or mixtures thereof.
- C n Sorb sorbitan monoalkylate
- C16EO2 polyoxyethylene glycol hexadecyl ether
- CigECh polyoxyethylene glycol stearyl ether
- polyethylene glycol monooleyl Ci8 :i E02
- oleyl phosphate oleyl acetate
- an oil-in-water emulsion wherein the hydrophilic surfactant is at least one hydrophilic surfactant selected from the group consisting of: nonionic polyoxyethylene alkyl ether (C IntelEO m ), polyoxyethylene sorbitan monoalkylate (C n SorbEO m ) where n is between 12 and 40 and where m is between 20 and 50; polyethylene glycol monooleyl ether (Ci 8:i EO m ) where m is between 7 and 20; polyoxyethylene octyl phenyl ether; anionic sodium dodecyl sulfate (SDS); sodium lauryl ether sulfate (SLES); cationic surfactant cetyltrimethyl ammonium bromide (CTAB); and cocamidopropyl betaine (CAPB) or mixtures thereof.
- nonionic polyoxyethylene alkyl ether C IntelEO m
- polyoxyethylene sorbitan monoalkylate C n SorbEO
- an oil-in-water emulsion wherein the emulsion is exposed to or treated to at least two cooling-heating cycles, at least three cooling-heating cycles, at least four cooling-heating cycles, at least five cooling-heating cycles, at least six cooling-heating cycles, at least seven cooling-heating cycles, at least eight cooling-heating cycles or more coolingheating cycles.
- the order in which the emulsions of the present invention are treated can be varied depending on the constituents of the emulsions which have been selected. In some embodiments the emulsion or any of the constituents can be exposed to cooling before heating. In some embodiments the emulsion or any of the constituents can be exposed to heating before cooling.
- the time or duration of heating of the emulsion can be varied depending on the constituents of the emulsions which have been selected.
- the emulsion or constituents of the emulsion can be exposed to heating for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40 or 50 seconds; 1, 2, 5, 10, 15, 20, 30, 40, 50, 60 minutes; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours or more.
- the time or duration of cooling of the emulsion can be varied depending on the constituents of the emulsions which have been selected.
- the emulsion or constituents of the emulsion can be exposed to cooling for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40 or 50 seconds; 1, 2, 5, 10, 15, 20, 30, 40, 50, 60 minutes; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours or more.
- the terms“cooling”,“freezing”,“re-cooling” and“re-freezing” are used interchangeably unless specifically stated otherwise or the context of the term dictates differently.
- the cooling or freezing temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C below the cooling or freezing temperature of the oil.
- the terms“heating”,“melting”,“re-heating” and“re-melting” are used interchangeably unless specifically stated otherwise or the context of the term dictates differently.
- the heating or melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the heating or melting temperature of the oil.
- the melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C above the heating or melting temperature of the triglyceride oil.
- the melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C above the melting temperature of tricaprin (CioTG), trilaurin (CnTG), trimyristin (CMTG), tripalmitin (Ci 6 TG) and tristearin (CisTG) or mixtures thereof.
- the freezing temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C below the freezing temperature of tricaprin (CioTG), trilaurin (CnTG), trimyristin (CMTG), tripalmitin (CMTG) and tristearin (CisTG) or mixtures thereof.
- CioTG trilaurin
- CMTG trimyristin
- CMTG tripalmitin
- Stearin CisTG
- an oil-in-water emulsion wherein the nanosized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised with at least one lipophilic surfactant and at least one hydrophilic surfactant.
- an emulsion comprising stabilised nano-sized self-emulsified particulates have a diameter of between about 12 nm to about 480 nm, about 14 nm to about 460 nm, about 16 nm to about 440 nm, about 18 nm to about 420 nm, about 20 nm to about 400 nm, about 22 nm to about 380 nm, about 24 nm to about 360 nm, about 26 nm to about 340 nm, about 28 nm to about 320 nm, 30 nm to about 300nm, about 35 nm to about 280 nm, about 40 nm of about 260nm, about 45 nm to about 240 nm, about 50 nm to about 220, about 55 nm to about 200, about 60 nm to about 180 nm, about 65 nm to about 160 nm, about 70 nm to about 140 nm, about 75
- an oil-in-water emulsion wherein the nanosized self-emulsified particulates with a diameter of about 20 nm.
- an oil-in-water emulsion wherein the centration of the stabilising lipophilic surfactant is between about 0.01% and about 2%, between about 0.025% and about 1.9%, between about 0.05% and about 1.8%, between about 0.1% and about 1.5%, between about 0.15% and about 1.25%, between about 0.2% and about 1%, between about 0.4% and about 0.8% of the total weight of the emulsion, and wherein the concentration of the stabilising hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion.
- an oil-in-water emulsion wherein the concentration of the stabilising lipophilic surfactant is 0.7%. In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the stabilising lipophilic surfactant is 2.9%.
- the concentration of the stabilising lipophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
- the concentration of the stabilising hydrophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
- an oil-in-water emulsion wherein the cooling rate of the cooling-heating cycle is between about 0.01 K min 1 and about 1000 K min 1 , between about 0.01 K min 1 and about 50 K min 1 , between about 0.025 K min 1 and about 45 K min 1 , between about 0.05 K min 1 and about 40 K min 1 , between about 0.075 K min 1 and about 35 K min 1 , between about 0.1 K min 1 and about 30 K min 1 , between about 0.125 K min 1 and about 25 K min 1 , between about 0.2 K min 1 and about 20 K min 1 , between about 0.4 K min 1 and about 15 K min 1 , between about 0.5 K min 1 and about 10 K min 1 , between about 0.75 K min 1 and about
- the cooling rate is about 1 K min 1 .
- an oil-in-water emulsion wherein the heating rate of the cooling-heating cycle is between about 0.01 K min 1 and about 10 K min 1 , between about 0.025 K min 1 and about 9.5 K min 1 , between about 0.05 K min 1 and about 9 K min 1 , between about 0.075 K min 1 and about 8.5 K min 1 , between about 0.1 K min 1 and about 8 K min 1 , between about 0.125 K min 1 and about 7.5 K min 1 , between about 0.2 K min 1 and about 7 K min 1 , between about 0.4 K min 1 and about 6.5 K min 1 , between about 0.5 K min 1 and about 6 K min 1 , between about 0.75 K min 1 and about 5.5 K min 1 , between about 1 K min 1 and about 5 K min 1 , between about 1.25 K min 1 and about 4.5 K min 1 , between about 1.5 K min 1 and about 4 K min 1 , between about 2 K min 1 and about 3 K min 1 .
- the heating rate of the cooling-heating cycle is between about 0.
- an oil-in-water emulsion comprising mixtures of triglycerides.
- the triglyceride is at least one selected from the group consisting of tripalmitin, trimyristin, trilaurin, coconut oil or other vegetable oil.
- the coconut oil is a mixture of triglycerides with about 47 % lauric chains, 16 % myristic chains, 10 % palmitic chains, 3% stearic chains, 7% caprylic chains, 8% decanoic chains, 7 % oleic chains and 2 % linoleic chains.
- the triglyceride oil can be selected from cottonseed oil, flaxseed oil, almond oil, safflower oil, palm oil, sunflower oil, avocado oil, soybean oil, com oil, canola oil, grapeseed oil, rapeseed oil, hazelnut oil, linseed oil, brazil nut oil, peanut oil, rice bran oil, hemp seed oil, olive oil, sesame oil, peanut oil, palm kernel oil, cocoa butter, butter, lard, tallow, medium chain triglyceride oil, long chain triglyceride oil.
- an oil-in-water emulsion containing mixtures of other oils such as diglycerides (diacylglycerols), mono-glycerides (monoacylglycerols), phospholipids, lysolipids.
- such mixtures are used as lipid drug delivery systems.
- the oil in the oil-in-water emulsion is an excipient for dissolving, dispersing, or otherwise delivering an active compound, though the oil can be an active ingredient itself.
- the active ingredient is at least one selected from the group consisting of flavours, flavour precursors, aromas, aroma precursors, taste enhancers, salts, sugars, amino-acids, polysaccharides, enzymes, peptides, proteins or carbohydrates, food supplements, food additives, hormones, bacteria, plant extracts, medicaments, drugs, pharmaceuticals, bio-pharmaceutical, biosimilars, vaccines, antigens, antibodies (Abs), peptibodies, antibody-drug-conjugates (ADCs), nutrients, chemicals for agrochemical or cosmetic applications, carotenoids, vitamins, antioxidants or nutraceuticals selected from the group comprising of lutein, lutein esters, [beta] -
- an oil-in-water emulsion wherein the emulsion is dried in a powder form.
- small angle X-ray scattering and Cryo-TEM can show that active ingredients and structure of the particulates of oil-in-water emulsion of the invention is reconstituted when the dried emulsion is reconstituted by addition of water.
- an oil-in-water emulsion wherein the emulsion is a starting material, an intermediate product or an additive to a final product.
- an oil-in-water emulsion wherein the starting material, the intermediate product or additive to a final product is a pharmaceutical, agro-chemical, consumer, food supplement or cosmetic starting material, the intermediate product or additive to a final product.
- an oil-in-water emulsion wherein the starting material, the intermediate product or additive to a final product has an increased shelf-life.
- an oil-in-water emulsion for use in enhancing stability, protection against chemical or enzymatic degradation or oxidation of an active ingredient in the oil-in-water emulsion.
- an oil-in-water emulsion for use in enhancing bioavailability, bioaccessibility or absorption of active ingredient during digestion.
- an oil-in-water emulsion for use in controlled release, burst release, or sustained release of an active ingredient during consumption or digestion.
- an oil-in-water emulsion for use in controlled release of aroma or flavour, burst release of aroma or flavour, or sustained release of aroma or flavour to create new or improved sensory or taste properties.
- an oil-in-water emulsion for use in creating different taste, different texture, mouth feel, mouth coating, or creaminess sensation.
- an oil-in-water emulsion for use in taste masking, off taste masking, flavour masking, off flavour masking, taste modulation or flavour modulation.
- a pharmaceutical combination comprising the oil- in-water emulsion of the present invention and at least one further pharmaceutically acceptable surfactant, excipient or additive.
- the pharmaceutical combination comprises the oil-in-water emulsion of the present invention and at least one or more pharmaceutically acceptable excipients or additive.
- a "pharmaceutically acceptable excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatine, vegetable oils and polyethylene glycols.
- the pharmaceutical combination comprises a therapeutically active ingredient.
- the therapeutically active ingredient is an anti-cancer agent.
- the anti-cancer agent is a chemotherapy agent.
- the anti-cancer agent is a biotherapeutic agent such as an antibody (Ab) or a functional derivative of an Ab.
- the active ingredient is an antimicrobial agent.
- the antimicrobial agent is an antibacterial agent such as an antibiotic.
- the melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C above the melting temperature of the oil.
- the freezing temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the oil.
- a method for producing an oil-in-water emulsion comprising the steps of: a. preparing an initial emulsion of a lipophilic phase in a hydrophilic phase to form oil droplets of a diameter greater than 1 pm in the presence of at least one lipophilic surfactant and at least one hydrophilic surfactant; and b. treating the initial emulsion to form an oil-in-water emulsion comprising nano-sized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm.
- the initial emulsion comprises an intermediate metastable phase.
- the initial emulsion is subjected to at least one cooling cycle.
- the oil is selected from the group consisting of vegetable oils, triglyceride oils, essential oils, flavouring oils, esters, alkanes, paraffins, waxes, diglycerides, phospholipids and mixtures thereof.
- the oil is triglyceride oil.
- the method requires usage of hydrophilic and/or lipophilic surfactant and controlled variation of the emulsion temperature around the cooling-heating or melting-freezing temperature of the triglyceride.
- the initial emulsion is treated by at least two cooling-heating cycles, at least three cooling-heating cycles, at least four cooling-heating cycles, at least five cooling-heating cycles, at least six cooling-heating cycles, at least seven cooling-heating cycles, at least eight cooling-heating cycles or more cooling-heating cycles.
- the heating temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the melting temperature of the triglyceride.
- the cooling temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C below the freezing temperature of the triglyceride.
- the nano-sized self- emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised.
- the stabilised nano-sized self- emulsified particulates have a diameter of between about 12 nm to about 280 nm, about 14 nm to about 260 nm, about 16 nm to about 240 nm, about 18 nm to about 220 nm, about 20 nm to about 200 nm, about 22 nm to about 180 nm, about 24 nm to about 160 nm, about 26 nm to about 140 nm, about 28 nm to about 120 nm, 30 nm to about lOOnm, about 35 nm to about 80 nm, about 40 nm of about 70 nm, about 45 nm to about 65 nm.
- of the method has a diameter of between about 12 nm to about 280 nm, about 14 nm to about 260
- the cooling rate is between about 0.01 K min 1 and about 1000 K min 1 , between about 0.01 K min 1 and about 50 K min 1 , between about 0.025 K min 1 and about 45 K min 1 , between about 0.05 K min 1 and about 40 K min 1 , between about 0.075 K min 1 and about 35 K min 1 , between about 0.1 K min 1 and about 30 K min 1 , between about 0.125 K min 1 and about 25 K min 1 , between about 0.2 K min 1 and about 20 K min 1 , between about 0.4 K min 1 and about 15 K min 1 , between about 0.5 K min 1 and about 10 K min 1 , between about 0.75 K min 1 and about 7.5 K min 1 , between about 1 K min 1 and about 5 K min 1 , between about 1.25 K min 1 and about 2.5 K min 1 , between about 1.5 K min 1 and about 2 K min 1 .
- the cooling rate is about 1 K min 1 .
- the heating rate is between about 0.01 K min 1 and about 10 K min 1 , between about 0.025 K min 1 and about 9.5 K min 1 , between about 0.05 K min 1 and about 9 K min 1 , between about 0.075 K min 1 and about 8.5 K min 1 , between about 0.1 K min 1 and about 8 K min 1 , between about 0.125 K min 1 and about 7.5 K min 1 , between about 0.2 K min 1 and about 7 K min 1 , between about 0.4 K min 1 and about 6.5 K min 1 , between about 0.5 K min 1 and about 6 K min 1 , between about 0.75 K min 1 and about 5.5 K min 1 , between about 1 K min 1 and about 5 K min 1 , between about 1.25 K min 1 and about 4.5 K min 1 , between about 1.5 K min 1 and about 4 K min 1 , between about 2 K min 1 and about 3 K min 1 .
- the heating rate of the cooling-heating cycle is about 1 K min
- Triglycerides used in the current invention are purchased from TCI, Alfa Aesar or Sigma-Aldrich and have analytical purity, > 80%, see Table 1.
- the surfactants used are presented in Table 2.
- the drop diameter by volume become 100 nm and after 4 freeze-thaw cycles, it becomes 20 nm. This drop diameter does not change if more freeze-thaw cycles are performed. Depending on the final temperature, the droplets could be liquid or solid.
- Figure 1(a) Illustrates the drop-size decrease observed with large scale or bulk emulsions.
- the smallest drop diameter which is reached after 4 consecutive freeze/thaw cycles for emulsion with 0.7 vol. % oil and drops with initial diameter around 20 pm is 20 nm.
- the emulsion is prepared with C M TG and stabilized by 1.5 wt.% CigEC o and 1 wt.% monopalmitin and monostearin mixture, dispersed in the aqueous phase.
- Figure 1(b) Illustrates the drop size decrease observed with large scale or bulk emulsions.
- the smallest drop or droplet diameter which is reached after 4 consecutive freeze/thaw cycles for emulsion with 2.9 vol. % oil and drops with initial diameter around 33.5 pm is 40 nm.
- the emulsion is prepared with C M TG and stabilized by 1.5 wt.% CigEC o and 1 wt.% monopalmitin and monostearin mixture, dispersed in the aqueous phase.
- Emulsion demonstrates the drop-size decrease observed in emulsions which are stored at 35°C without heating and/or additional cooling.
- the initial emulsion is prepared by membrane emulsification and drops or droplet have initial diameter of 35 pm.
- Emulsion contains 2.9 vol. % emulsified C M TG and water phase containing 1.5 wt. % Brij S20 and 1 wt. % monopalmitin and monostearin mixture.
- the emulsion drops are prepared at temperature of 335 K.
- the emulsion is placed in a glass capillary which is sealed and stored at 35°C.
- the emulsion is observed under a microscope upon different periods of storage, see Figure 2. Drop disintegration upon storage is observed. The particles that form upon the disintegration have diameter smaller than 1 pm.
- Figure 2 Depicts the particle disintegration observed upon storage of the emulsion. Particle disintegration observed with C M TG sample stored at 35°C. After 19 h at 35°C, the particle volume noticeably increased and the disintegration process has already begun. After 67 h, significant fraction of the particles has already disintegrated. The reason for the lower contrast of this image is the appearance of numerous small droplets which scatter the light illuminating the sample. These observations are performed in a glass capillary which was stored in a thermostat at 35°C and was observed at certain time intervals, as indicated in the images.
Abstract
The present invention is directed to an oil-in-water emulsion and methods in which the oil droplets exhibit self-emulsified particulates of a nano-sized diameter and within a narrow size range for used to deliver or store ingredients and provide a new or improved functionality.
Description
OIL-IN-WATER EMULSION OF NANO-SIZED SELF-EMULSIFIED PARTICULATES
[1] The present invention is directed to an oil-in-water emulsion and methods in which the oil droplets exhibit self-emulsified particulates of a nano-sized diameter and within a narrow size range for used to deliver or store ingredients and provide a new or improved functionality.
INTRODUCTION
[2] Oil-in-water emulsions are widely used in food, cosmetic, agrochemical, zootechnical and pharma industries. Such emulsions can be exploited for many different purposes or applications such as delivering ingredients, or creating a certain feel, texture, fragrance or sensation as well as taste or smoothness. In industry, emulsions also deliver active compounds, such as, flavours, vitamins, antioxidants, nutraceuticals, phytochemicals, drugs, chemicals, enzymes, antibodies, peptibodies, vaccines, viral vectors, hormone therapies, gene-editing techniques, biosimilars and others. Administering active components requires the use of an appropriate vehicle for bringing an effective amount of the active component into a desired place of action. Oil-in-water emulsions are commonly used as delivery systems since they take advantage of the solubility of lipophilic compounds in the oil. Dissolution of active compounds, such as phytosterols, carotenoids or water- insoluble drugs into the oil droplets of emulsions or dispersions not only aids dispersibility (homogeneous incorporation of the active elements), but can also increase their bioavailability. Clinical and animal experiments have demonstrated better efficacy and bioavailability of active compounds, such as drugs and nutrients, when the active compounds are dissolved or solubilised, for instance into nano-emulsions or nano-dispersions.
[3] Recently, particular interest has been expressed in using triglyceride-based emulsions or dispersions such as triglyceride nano-emulsions or nano-dispersions as an alternative to other oils in different industrial applications. Such triglyceride nano-emulsions or nano-dispersions are, however, usually obtained via high-pressure homogenization (HPH) or by ultra-sonication (known as high-energy methods) and the typical drop size is in the range of 150 to 300 nm [1-3]
[4] The problem with HPH or sonication methods is the generation of undesirable heat which not only increases the cost of production but also poses real difficulties with commercial scale up. Furthermore, these methods are not applied to temperature-sensitive compounds and the size and range of the drops further restricts applications.
[5] There is a therefore a need for generating further oil-in-water nano-emulsions which are able to address at least some of the above shortcomings.
SUMMARY
[6] Here is disclosed an oil-in-water emulsion, comprising particulates with a diameter range of between about 10 nm to about 500 nm.
[7] In one aspect of the present invention there is provided an oil-in-water emulsion wherein oil droplets of a diameter greater than 1 pm exhibit nano-sized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm, due to the presence of:
a. at least one lipophilic surfactant; and/or
b. at least one hydrophilic surfactant.
[8] In some embodiments there is provided an oil-in-water emulsion wherein the oil-inwater emulsion comprises an active ingredient.
[9] In some embodiments there is provided an oil-in-water emulsion wherein the active ingredient is lipophilic.
[10] In some embodiments there is provided an oil-in-water emulsion wherein the active ingredient is between 0.0001% and 50% of the total weight of the emulsion.
[11] In some embodiments there is provided an oil-in-water emulsion wherein the emulsion comprises disseminated oil droplets having nano-sized self-emulsified particulates comprising: i) oil selected from the group consisting of triglyceride oil, vegetable oil, essential oil, flavouring oil, esters and mixtures thereof;
ii) at least one lipophilic surfactant (Hydrophilic-Lipophilic Balance, HLB < 10) and/or at least one hydrophilic surfactant with HLB value > 10.
[12] In some embodiments there is provided an oil-in-water emulsion wherein the oil is selected from the group consisting of vegetable oils, triglyceride oils, essential oils, flavouring oils, esters, alkanes, paraffins, waxes, diglycerides, phospholipids and mixtures thereof.
[13] In some embodiments there is provided an oil-in-water emulsion wherein the oil is triglyceride oil.
[14] In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is selected from the group consisting of tricaprin (CioTG), trilaurin (C12TG), trimyristin (C14TG), tripalmitin (C16TG) and tristearin (CisTG) or mixtures thereof.
[15] In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is between about 0.01% and about 20%, between about 0.01% and about 10%, between about 0.01% and about 5%, between about 0.025% and about 1.9%, between about 0.05% and about 1.8%, between about 0.1% and about 1.5%, between about 0.15% and about 1.25%, between about 0.2% and about 1%, between about 0.4% and about 0.8% of the total weight of the emulsion, and wherein the concentration of the hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion. In some embodiments there is
provided an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is 0.7%. In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is 2.9%.
[16] In some embodiments there is provided an oil-in-water emulsion wherein for 1% oil content in the emulsion the preferred concentration of the lipophilic surfactant is between about 0.01% and about 3%, between about 0.025% and about 2.8%, between about 0.05% and about 2.6%, between about 0.1% and about 2.4%, between about 0.2% and about 2%, between about 0.4% and about 2%, between about 0.8% and about 1.8% of the total weight of the emulsion, and wherein the concentration of the hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion.
[17] In some embodiments there is provided an oil-in-water emulsion wherein for 1% oil content in the emulsion the preferred concentration of the lipophilic surfactant is between about 0.8% and about 1.8% of the total weight of the emulsion.
[18] In some embodiments there is provided an oil-in-water emulsion wherein for 1% oil content in the emulsion the preferred concentration of lipophilic surfactant is about 1.5% of the weight of the total emulsion and the concentration of the hydrophilic surfactant is about 1% of the weight of the total emulsion.
[19] In some embodiments, for different oil content (volume fraction f), the preferred amount of surfactant c for the hydrophilic surfactant could be estimated by the formula [4]: c = 6fG/[(1- f) ds2] while for the lipophilic surfactant c = 6G 32
[20] , where c is the minimal needed surfactant concentration; f is the oil volume fraction; G is the monolayer surfactant adsorption and d32 is the mean volume-surface diameter of the droplets in the produced emulsion [4]
[21] In at least one embodiment, the concentration of the lipophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
[22] In at least one embodiment, the concentration of the hydrophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
[23] In some embodiments there is provided an oil-in-water emulsion wherein the lipophilic surfactant is at least one lipophilic surfactant selected from the group consisting of sorbitan monoalkylate (CnSorb) where n is between 12 and 18; polyoxyethylene glycol hexadecyl ether (C16EO2), polyoxyethylene glycol stearyl ether (CisEC ), polyethylene glycol monooleyl (Ci8:iE02), oleyl phosphate, oleyl acetate and 1-oleoyl-rac-glycerol (monoolein), glucoside-based
surfactants, diglyceride surfactants, phospholipid surfactants, as well as surfactants that are not only used for stabilization only but where the surfactant is also an active ingredient itself.
[24] In some embodiments there is provided an oil-in-water emulsion wherein the hydrophilic surfactant is at least one hydrophilic surfactant selected from the group consisting of: nonionic polyoxyethylene alkyl ether (C„EOw), polyoxyethylene sorbitan monoalkylate (CnSorbEOm) where n is between 12 and 40 and where m is between 20 and 50; polyethylene glycol monooleyl ether (Ci8:iEOm) where m is between 7 and 20; polyoxyethylene octyl phenyl ether; anionic sodium dodecyl sulfate (SDS); sodium lauryl ether sulfate (SLES); cationic surfactant cetyltrimethyl ammonium bromide (CTAB); and cocamidopropyl betaine (CAPB), glucoside- based surfactants (such as alkyl polyglycosides, glycopeptides and esters), peptide amphiphiles, aminoacid surfactants, diglyceride surfactants, phospholipid surfactants, as well as surfactants that are not only used for stabilization only but where the surfactant is also an active ingredient itself, and surfactants which contain reactive groups and thus could be used subsequently for crosslinking a surface layer around an emulsified droplet.
[25] In some embodiments there is provided an oil-in-water emulsion wherein the emulsion is exposed to at least two cooling-heating cycles, at least three cooling-heating cycles, at least four cooling-heating cycles, at least five cooling-heating cycles, at least six cooling-heating cycles, at least seven cooling-heating cycles, at least eight cooling-heating cycles or more cooling-heating cycles.
[26] In some embodiments of the method of the present invention, the heating temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the melting temperature of the oil.
[27] In some embodiments of the method of the present invention, the cooling temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the oil.
[28] In some embodiments of the method of the present invention, the heating temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the melting temperature of the triglyceride.
[29] In some embodiments of the method of the present invention, the cooling temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the triglyceride.
[30] In some embodiments there is provided an oil-in-water emulsion wherein the nanosized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised with at least one lipophilic surfactant and at least one hydrophilic surfactant. In some embodiment, there is provided an emulsion comprising stabilised nano-sized self-emulsified particulates have a diameter of between about 12 nm to about 480 nm, about 14 nm to about 460
nm, about 16 nm to about 440 nm, about 18 rnn to about 420 nm, about 20 nm to about 400 ran, about 22 nm to about 380 nm, about 24 nm to about 360 nm, about 26 nm to about 340 nm, about 28 nm to about 320 nm, 30 nm to about 300nm, about 35 nm to about 280 nm, about 40 nm of about 260nm, about 45 nm to about 240 nm, about 50 nm to about 220, about 55 nm to about 200, about 60 nm to about 180 nm, about 65 nm to about 160 nm, about 70 nm to about 140 nm, about 75 nm to about 120 nm, about 80 nm to about 100 nm.
[31] In some embodiments there is provided an oil-in-water emulsion wherein over 70% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 75% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 80% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 85% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 90% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 95% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 96% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 97% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 98% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 99% of the nano-sized self-emulsified particulates have a diameter in the range of about 10 nm to about 100 nm.
[32] In some embodiments, there is provided an oil-in-water emulsion wherein the nanosized self-emulsified particulates exhibit a diameter of about 20 nm to about 50 nm.
[33] In some embodiments there is provided an oil-in-water emulsion wherein over 70% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 75% of the nano-sized self- emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 80% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 85% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 90% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein
over 95% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 96% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 97% of the nano-sized self- emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 98% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 99% of the nano-sized self-emulsified particulates have a diameter of about 20 nm to about 50 nm. In some embodiments, there is provided an oil-in-water emulsion wherein the nano-sized self-emulsified particulates exhibit a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 70% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 75% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 80% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 85% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 90% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 95% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 96% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 97% of the nano-sized self- emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 98% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm. In some embodiments there is provided an oil-in-water emulsion wherein over 99% of the nano-sized self-emulsified particulates have a diameter of about 10 nm to about 40 nm.
[34] In some embodiments, there is provided an oil-in-water emulsion wherein the nanosized self-emulsified particulates exhibit a diameter of about 20 nm.
[35] In some embodiments, there is provided an oil-in-water emulsion wherein over 70% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm. In some embodiments, there is provided an oil-in-water emulsion wherein over 75% or more of the nanosized self-emulsified particulates exhibit a diameter of about 20 nm. In some embodiments, there is provided an oil-in-water emulsion wherein over 80% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm. In some embodiments, there is provided an oil-inwater emulsion wherein over 85% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm. In some embodiments, there is provided an oil-in-water emulsion wherein over 90% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm.
In some embodiments, there is provided an oil-in-water emulsion wherein over 95% or more of the nano-sized self-emulsified particulates exhibit a diameter of about 20 nm.
[36] In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the stabilising lipophilic surfactant is between about 0.01% and about 20%, between about 0.01% and about 10%, between about 0.01% and about 5%, between about 0.01% and about 2%, between about 0.025% and about 1.9%, between about 0.05% and about 1.8%, between about 0.1 % and about 1.5%, between about 0.15% and about 1.25%, between about 0.2% and about 1%, between about 0.4% and about 0.8% of the total weight of the emulsion, and wherein the concentration of the stabilising hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion.
[37] In at least one embodiment, the concentration of the stabilising lipophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
[38] In at least one embodiment, the concentration of the stabilising hydrophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
[39] In some embodiments there is provided an oil-in-water emulsion wherein the cooling rate of the cooling-heating cycle is between about 0.01 K min 1 and about 1000 K min 1, between about 0.025 K min 1 and about 50 K min 1, between about 0.05 K min 1 and about 40 K min 1, between about 0.075 K min 1 and about 35 K min 1, between about 0.1 K min 1 and about 30 K min 1, between about 0.125 K min 1 and about 25 K min 1, between about 0.2 K min 1 and about 20 K min 1, between about 0.4 K min 1 and about 15 K min 1, between about 0.5 K min 1 and about 10 K min 1, between about 0.75 K min 1 and about 7.5 K min 1, between about 1 K min 1 and about 5 K min 1, between about 1.25 K min 1 and about 2.5 K min 1, between about 1.5 K min 1 and about 2 K min 1. In some embodiments the cooling rate is about 1 K min 1.
[40] In some embodiments there is provided an oil-in-water emulsion wherein the self- emulsification can happen in the frozen state without heating, or where the heating rate of the cooling-heating cycle is between about 0.01 K min 1 and about 1000 K min 1.
[41] In some embodiments there is provided an oil-in-water emulsion wherein selfemulsification occurs at constant temperature.
[42] In some embodiments there is provided an oil-in-water emulsion wherein self- emulsification occurs at between about 33°C and about 37°C.
[43] In some embodiments there is provided an oil-in-water emulsion wherein self- emulsification occurs at about 35°C.
[44] In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride is at least one selected from the group consisting of trimyristine, trilaurine, tristearine and tripalmitine.
[45] In some embodiments there is provided an oil-in-water emulsion wherein the active ingredient is at least one selected from the group consisting of flavours, flavour precursors, aromas, aroma precursors, taste enhancers, salts, sugars, amino-acids, polysaccharides, enzymes, peptides, proteins or carbohydrates, food supplements, food additives, hormones, bacteria, plant extracts, medicaments, drugs, pharmaceuticals, bio-pharmaceutical, biosimilars, vaccines, antigens, antibodies (Abs), peptibodies, antibody-drug-conjugates (ADCs), nutrients, chemicals for agrochemical or cosmetic applications, carotenoids, vitamins, antioxidants or nutraceuticals selected from the group comprising of lutein, lutein esters, [beta] -carotene, tocopherol, tocopherol acetate, tocotrienol, lycopene, Co-QlO, flax seed oil, fish oil, omega-3 oils, omega-6 oils, DHA, EPA, arachidonic-rich oils, LCPUFA oils, menthol, mint oil, lipoic acid, vitamins, polyphenols and their glycosides, ester and/or sulphate conjugates, isoflavones, flavonols, flavanones and their glycosides such as hesperidin, flavan 3-ols comprising catechin monomers and their gallate esters such as epigallocatechin gallate and their procyanidin oligomers, vitamin C, vitamin C palmitate, vitamin A, vitamin B12, vitamin D, CC-and [gamma] -polyunsaturated fatty acids, phytosterols, esterified phytosterol, non-esterified phytosterol, zeaxanthine, caffeine and a combination thereof.
[46] The present emulsions are suitable for use in the food industry such as ice-cream sector, mayonnaise sector or margarine sector.
[47] In some embodiments there is provided an oil-in-water emulsion for used in the food industry.
[48] In some embodiments there is provided an oil-in-water emulsion for use in making an ice-cream product.
[49] In some embodiments there is provided an oil-in-water emulsion for use in making mayonnaise.
[50] In some embodiments there is provided an oil-in-water emulsion for use in making margarine.
[51] In some embodiments there is provided an oil-in-water emulsion wherein the emulsion is dried in a powder form.
[52] In some embodiments there is provided an oil-in-water emulsion wherein the emulsion is a starting material, an intermediate product or an additive to a final product.
[53] In some embodiments there is provided an oil-in-water emulsion wherein the starting material, the intermediate product or additive to a final product is a pharmaceutical, agro-chemical, consumer, food supplement or cosmetic starting material, the intermediate product or additive to a final product.
[54] In some embodiments there is provided an oil-in-water emulsion wherein the starting material, the intermediate product or additive to a final product has an increased shelf-life.
[55] In some embodiments there is provided an oil-in-water emulsion for use in enhancing stability, protection against chemical or enzymatic degradation or oxidation of an active ingredient in the oil-in-water emulsion.
[56] In some embodiments there is provided an oil-in-water emulsion for use in enhancing bioavailability, bioaccessibility or absorption of active ingredient during digestion.
[57] In some embodiments there is provided an oil-in-water emulsion for use in controlled release, burst release, or sustained release of an active ingredient during consumption or digestion.
[58] In some embodiments there is provided an oil-in-water emulsion for use in controlled release of aroma or flavour, burst release of aroma or flavour, or sustained release of aroma or flavour to create new or improved sensory or taste properties.
[59] In some embodiments there is provided an oil-in-water emulsion for use in creating different taste, different texture, mouth feel, mouth coating, or creaminess sensation.
[60] In some embodiments there is provided an oil-in-water emulsion for use in taste masking, off taste masking, flavour masking, off flavour masking, taste modulation or flavour modulation.
[61] Here we also disclose a one aspect a pharmaceutical combination comprising the oil- in-water emulsion of the present invention and at least one further pharmaceutically acceptable surfactant, excipient or additive.
[62] In some embodiments there is provided a pharmaceutical combination for use in medicine.
[63] Here we also describe a low-energy method which leads to oil-in-water nanoemulsions, containing particulates with a diameter range between about 10 nm to about 500 nm. The method requires the usage of hydrophilic and/or lipophilic surfactant(s) and controlled variation of the emulsion temperature around melting temperature of the oil. In some embodiments of the method of the present invention, the melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C above the melting temperature of the oil. In some embodiments of the method of the present invention, the freezing temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the oil.
[64] According to one aspect of the present invention, there is provided a method for producing an oil-in-water emulsion according to the present invention, wherein the method comprising the steps of:
a. preparing an initial emulsion of a lipophilic phase in a hydrophilic phase to form oil droplets of a diameter greater than 1 pm in the presence of at least one lipophilic surfactant and/or at least one hydrophilic surfactant; and
b. treating the initial emulsion to form an oil-in-water emulsion comprising nano-sized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm.
[65] In some embodiments of the method of the present invention, wherein the initial emulsion comprises an intermediate metastable phase.
[66] In some embodiments of the method of the present invention, the initial emulsion is subjected to at least one fast cooling cycle.
[67] In some embodiments of the method of the present invention, the oil is selected from the group consisting of vegetable oils, triglyceride oils, essential oils, flavouring oils, esters, alkanes, paraffins, waxes, diglycerides, phospholipids and mixtures thereof.
[68] In some embodiments of the method of the present invention, the oil is triglyceride oil.
[69] In some embodiments of the present invention, the method requires a combination of hydrophilic surfactants and lipophilic surfactants and controlled variation of the emulsion temperature around the cooling-heating or melting-freezing temperature of the triglyceride.
[70] In some embodiments of the method of the present invention, the initial emulsion is treated by at least two cooling-heating cycles, at least three cooling-heating cycles, at least four cooling-heating cycles, at least five cooling-heating cycles, at least six cooling-heating cycles, at least seven cooling-heating cycles, at least eight cooling-heating cycles or more cooling-heating cycles.
[71] In some embodiments of the method of the present invention, the heating temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the melting temperature of the triglyceride.
[72] In some embodiments of the method of the present invention, the cooling temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the triglyceride.
[73] In some embodiments of the method of the present invention, the nano-sized self- emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised. In some embodiments of the method of the present invention, the stabilised nano-sized self- emulsified particulates have a diameter of between about 12 nm to about 480 nm, about 14 nm to about 460 nm, about 16 nm to about 440 nm, about 18 nm to about 420 nm, about 20 nm to about 400 nm, about 22 nm to about 380 nm, about 24 nm to about 360 nm, about 26 nm to about 340 nm, about 28 nm to about 320 nm, 30 nm to about 300nm, about 35 nm to about 280 nm, about 40
nm of about 260nm, about 45 nm to about 240 nm, about 50 nm to about 220, about 55 nm to about 200, about 60 nm to about 180 nm, about 65 nm to about 160 nm, about 70 nm to about 140 nm, about 75 nm to about 120 nm, about 80 nm to about 100 nm.
[74] In some embodiments of the method of the present invention, the cooling rate is between about 0.01 K min 1 and about 1000 K min 1, between about 0.01 K min 1 and about 50 K min 1, between about 0.025 K min 1 and about 45 K min 1, between about 0.05 K min 1 and about 40 K min 1, between about 0.075 K min 1 and about 35 K min 1, between about 0.1 K min 1 and about 30 K min 1, between about 0.125 K min 1 and about 25 K min 1, between about 0.2 K min 1 and about 20 K min 1, between about 0.4 K min 1 and about 15 K min 1, between about 0.5 K min 1 and about 10 K min 1, between about 0.75 K min 1 and about 7.5 K min 1, between about 1 K min 1 and about 5 K min 1, between about 1.25 K min 1 and about 2.5 K min 1, between about 1.5 K min 1 and about 2 K min 1. In some embodiments the cooling rate is about 1 K min 1.
[75] In some embodiments of the method of the present invention, the heating rate is between about 0.01 K min 1 and about 10 K min 1, between about 0.025 K min 1 and about 9.5 K min 1, between about 0.05 K min 1 and about 9 K min 1, between about 0.075 K min 1 and about 8.5 K min 1, between about 0.1 K min 1 and about 8 K min 1, between about 0.125 K min 1 and about 7.5 K min 1, between about 0.2 K min 1 and about 7 K min 1, between about 0.4 K min 1 and about 6.5 K min 1, between about 0.5 K min 1 and about 6 K min 1, between about 0.75 K min 1 and about 5.5 K min 1, between about 1 K min 1 and about 5 K min 1, between about 1.25 K min 1 and about 4.5 K min 1, between about 1.5 K min 1 and about 4 K min 1, between about 2 K min 1 and about 3 K min 1. In some embodiments, the heating rate of the cooling-heating cycle is about 1 K min 1.
BRIEF DESCRIPTION OF THE DRAWINGS
[76] FIG 1 Illustrates the drop or droplet size decrease observed with large scale or bulk emulsions - FIG 1(a) and FIG 1(b).
[77] FIG 2 Depicts the particle disintegration observed upon storage of the emulsion.
DETAILED DESCRIPTION
[78] Throughout this disclosure, various publications, patents and published patent specifications are referenced by an identifying citation. The disclosures of these publications, patents and published patent specifications are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this disclosure pertains.
[79] As used herein, certain terms may have the following defined meanings.
[80] As used in the specification and claims, the singular form“a,”“an” and“the” include singular and plural references unless the context clearly dictates otherwise. For example, the term “a surfactant” or“a triglyceride” includes a single surfactant or triglyceride as well as a plurality of surfactants or triglycerides, including mixtures thereof.
[81] As used herein, the term "comprising" means including, made up of, composed of encompass, consist of, constitute and incorporate.
[82] All numbers or numerals as used herein that indicate amounts, ratios of materials, physical properties of materials, and/or use are to be understood as modified or qualified by the term "about," except as otherwise explicitly indicated.
[83] As used herein, the term "about" includes the recited number or number and +/- 10% from the recited numeral or number. By way of non-limiting example, the term "about ten (10)" would encompass nine (9) to eleven (11) or 9-11.
[84] As used in the specification and claims, the term“self-emulsification” refers to a reduction of size or diameter of oil droplets or drop as a result of temperature changes without physical or mechanically induced agitation or disruption of the drops. In some embodiments selfemulsification can be attained by cooling and/or heating the drops. For instance, self-emulsification of oil droplets of a diameter greater than 1 pm can undergo a reduction in the size or diameter, in the range of between about 10 nm to about 500 nm without physically or mechanically induced agitation or disruption of the droplets. In some embodiments, the temperature could be set stationary (e.g. with cooling the droplets at a substantially fixed or constant temperature - Example 2). For instance, self-emulsification can occur without heating and/or cooling cycle. In some embodiments there is provided an oil-in-water emulsion wherein self-emulsification occurs at constant temperature. In some embodiments there is provided an oil-in-water emulsion wherein self-emulsification occurs at between about 33°C and about 37°C. In some embodiments there is provided an oil-in-water emulsion wherein self-emulsification occurs at about 35°C. As used herein the terms“drop” or“droplet” are used interchangeably unless stated otherwise or the context dictates otherwise.
[85] As used herein“size” is measured on a volumetric-averaged basis, unless otherwise specified. The“particulate” or“droplet” in the present invention is a concept, unless otherwise specified, which can encompass not only a particulate or droplet but a particulate or droplet emulsion composed or comprising of agglomeration of such particulates or droplets.
[86] In some embodiments, the size is measured using any method know in the art which is suitable for the particular purpose. In some embodiments, the size of the droplets, for example in the case of micro-size dimensions, is determined using optical microscopy [5] In some embodiments the size of the particulates, for example in the case of nano-size dimentions, is determined using dynamic light scattering (DLS) by statistically corelating the Brownian motion fluctuations of the particulates [6]
[87] As used in the specification and claims, the term“exhibit” refers to self-emulsified emulsion which displays or incorporates nano-sized particulates of diameter in the range of about 10 nm to about 500 nm.
[88] In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 1000 Celsius degrees per minute, or higher. In some embodiments, the
temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 2000 Celsius degrees per minute (°C/min), or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 3000 °C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 4000 °C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 5000 °C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 6000°C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 8000 °C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 9000 °C/min, or higher. In some embodiments, the temperature can be changed at a controlled cooling rate, e.g. between 0.0001 and 10000 °C/min.
[89] As used in the specification and claims, the term“lipophilic surfactant” refers to surfactants which are soluble in lipids or oils. For instance, lipophilic surfactants include sorbitan monoalkylates (CnSorb) with n varied between 12 and 18, polyoxyethylene glycol hexadecyl ether (C16EO2), polyoxyethylene glycol stearyl ether (CisEC ), polyethylene glycol monooleyl ether with 2 ethoxy units (CisuECh), oleyl phosphate, oleyl acetate and 1 -oleoyl-rac-glycerol (monoolein). Without wishing to be bound by theory, surfactants with HLBdO are oil soluble or lipophilic (see Table 2 and Examples).
[90] As used in the specification and claims, the term“hydrophilic surfactant” refers to water-soluble nonionic, anionic, cationic or zwitterionic surfactants. For instance, nonionic hydrophilic surfactants includes, polyoxyethylene alkyl ethers (C„EOw) and polyoxyethylene sorbitan monoalkylates (CnSorbEOm) where n can be any one of between 12 and 40, and where m can be any one of between 20 and 50, polyethylene glycol monooleyl ethers (Ci8:iEOm) where m can be any one of between 7 and 20, and polyoxyethylene octyl phenyl ether (trade name Triton X100); anionic hydrophilic surfactants include sodium dodecyl sulfate (SDS) and sodium lauryl ether sulfate (SLES); cationic hydrophilic surfactants include cetyltrimethyl ammonium bromide (CTAB); and zwitterionic hydrophilic surfactants include cocamidopropyl betaine (CAPB). Without wishing to be bound by theory, surfactants with HLB > 10 are water soluble or hydrophilic (see Table 2 and Examples).
[91] In some embodiments, the at least one lipophilic surfactant and the at least one hydrophilic surfactant, have a resulting HLB value (Hydrophilic-Lipophilic Balance) of less (<) than any one of 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4 or less.
[92] In some embodiments the at least one lipophilic surfactant HLB value (Hydrophilic- Lipophilic Balance) < 10, and the at least one hydrophilic surfactant HLB value is (greater or equal to) > 10.
[93] As used in the specification and claims, the term“active ingredient” refers to at least one ingredient selected from but are not limited to, lipophilic active compounds or a salt, isomer, ester, ether or other derivative thereof selected from: a) acetylcholinesterase inhibitors; b) analgesics and nonsteroidal antiinflammatory agents (NS ALA) selected from aloxiprin, auranofin,
azapropazone, benorylate, capsaicin, celecoxib, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen calcium, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, leflunomide, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, rofecoxib, sulindac, tetrahydrocannabinol, tramadol and tromethamine; c) anthelminthics selected from albendazole, bephenium hydroxynaphthoate, cambendazole, dichlorophen, fenbendazole, ivermectin, mebendazole, oxamniquine, oxfendazole, oxantel embonate, praziquantel, pyrantel embonate and thiabendazole; d) antiacne agents such as isotretinoin and tretinoin; e) anti-anginal agents selected from amyl nitrate, glyceryl trinitrate (nitroglycerin), isosorbide dinitrate, isosorbide mononitrate, pentaerythritol tetranitrate, and ubidecarenone (coenzyme Q10); f) anti-asthma agents selected from zileuton, zafirlukast, terbutaline sulfate, montelukast, and albuterol; g) antibacterial agents, including antibiotics, selected from alatrofloxacin, azithromycin, aztreonum, baclofen, benzathine penicillin, cefixime, cefuraxime axetil, cinoxacin, ciprofloxacin HC1, clarithromycin, clofazimine, cloxacillin, demeclocycline, dirithromycin, doxycycline, erythromycin, ethionamide, furazolidone, grepafloxacin, imipenem, levofloxacin, lorefloxacin, moxifloxacin HC1, nalidixic acid, nitrofurantoin, norfloxacin, ofloxacin, phenoxymethyl penicillin, rifabutine, rifampicin, rifapentine, sparfloxacin, spiramycin, sulphabenzamide, sulphadoxine, sulphamerazine, sulphacetamide, sulphadiazine, sulphafurazole, sulpha-methoxazole, sulphapyridine, tetracycline, trimethoprim, trovafloxacin, and vancomycin; h) anticancer agents and immunosuppressants selected from abarelix, aldesleukin, alemtuzumab, alitretinoin, all-trans retinoic acid (ATRA), altretamine, amifostine, aminoglutethimide, amsacrine, anastrozole, arsenic trioxide, asparaginase, azacitidine, azathioprine, BCG Live, bevacuzimab (avastin), bexarotene, bicalutamide, bisantrene, bleomycin, bortezomib, busulfan, calusterone, camptothecin, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cyclosporin, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, daunorubicin, denileukin, dexrazoxane, docetaxel, doxorubicin (neutral), doxorubicin HC1, dromostanolone propionate, ellipticine, enlimomab, estramustine, epirubicin, epoetin alfa, erlotinib, estramustine, etoposide, exemestane, filgrastim, floxuridine fludarabine, fulvestrant, gefitinib, gemcitabine, gemtuzumab, goserelin acetate, histrelin acetate, hydroxyurea, ibritumomab, idarubicin, ifosfamide, imatinib mesylate, interferon alfa-2a, interferon alfa-2b, irinotecan, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, megestrol acetate, melphalan, mercaptopurine, mesna, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, mofetil mycophenolate, nandrolone, nelarabine, nilutamide, nofetumomab, oprelvekin, oxaliplatin, paclitaxel, palifermin, pamidronate, pegademase, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, porfimer sodium, procarbazine, quinacrine, rasburicase, rituximab, sargramostim, sirolimus, sorafenib, streptozocin, sunitinib maleate, tacrolimus, tamoxifen citrate, temozolomide, teniposide, testolactone, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, zoledronate, and zoledronic acid; i) anticoagulants selected from cilostazol, clopidogrel, dicumarol, dipyridamole, nicoumalone, oprelvekin, phenindione, ticlopidine, and tirofiban; j) antidiabetics selected from acetohexamide,
chlorpropamide, glibenclamide, gliclazide, glipizide, glimepiride, glyburide, miglitol, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide and troglitazone; k) antifungal agents selected from amphotericin, butenafine HC1, butoconazole nitrate, clotrimazole, econazole nitrate, fluconazole, flucytosine, griseofulvin, itraconazole, ketoconazole, miconazole, natamycin, nystatin, sulconazole nitrate, oxiconazole, terbinafine HC1, terconazole, tioconazole and undecenoic acid; 1) antihypertensive agents selected from amlodipine, benidipine, benezepril, candesartan, captopril, darodipine, dilitazem HC1, diazoxide, doxazosin HC1, enalapril, eposartan, losartan mesylate, felodipine, fenoldopam, fosenopril, guanabenz acetate, irbesartan, isradipine, lisinopril, minoxidil, nicardipine HC1, nifedipine, nimodipine, nisoldipine, phenoxybenzamine HC1, prazosin HC1, quinapril, reserpine, terazosin HC1, telmisartan, and valsartan; m) antithyroid agents selected from carbimazole and propylthiouracil; n) antiviral agents selected from abacavir, amprenavir, delavirdine, efavirenz, indinavir, lamivudine, nelfinavir, nevirapine, ritonavir, saquinavir, and stavudine; o) anxiolytics, sedatives, hypnotics and neuroleptics selected from alprazolam, amylobarbitone, barbitone, bentazepam, bromazepam, bromperidol, brotizolam, butobarbitone, carbromal, chlordiazepoxide, chlormethiazole, chlorpromazine, chlorprothixene, clonazepam, clobazam, clotiazepam, clozapine, diazepam, droperidol, ethinamate, flunanisone, flunitrazepam, triflupromazine, flupenthixol decanoate, fluphenthixol decanoate, flurazepam, gabapentin, haloperidol, lorazepam, lormetazepam, medazepam, meprobamate, mesoridazine, methaqualone, methylphenidate, midazolam, molindone, nitrazepam, olanzapine, oxazepam, pentobarbitone, perphenazine pimozide, prochlorperazine, propofol, pseudoephedrine, quetiapine, risperidone, sertindole, sulpiride, temazepam, thioridazine, triazolam, zolpidem, and zopiclone; p) beta-blockers selected from acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, pindolol and propranolol; q) cardiac inotropic agents selected from anrinone, digitoxin, digoxin, enoximone, lanatoside C and medigoxin; r) corticosteroids selected from beclomethasone, betamethasone, budesonide, cortisone acetate, desoxymethasone, dexamethasone, fludrocortisone acetate, flunisolide, fluocortolone, fluticasone propionate, hydrocortisone, methylprednisolone, prednisolone, prednisone and triamcinolone; s) diuretics selected from acetazolamide, amiloride, bendroflumethiazide, bumetanide, chlorothiazide, chlorthalidone, ethacrynic acid, frusemide, metolazone, spironolactone and triamterene; t) gastrointestinal compounds selected from bisacodyl, cimetidine, cisapride, diphenoxylate HC1, domperidone, famotidine, lanosprazole, loperamide, mesalazine, nizatidine, omeprazole, ondansetron HC1, pantoprazole, rabeprazole sodium, ranitidine HC1 and sulphasalazine; u) histamine Hi- and H2-receptor antagonists selected from acrivastine, astemizole, chlorpheniramine, cinnarizine, cetrizine, clemastine fumarate, cyclizine, cyproheptadine HC1, dexchlorpheniramine, dimenhydrinate, fexofenadine, flunarizine HC1, loratadine, meclizine HC1, oxatomide, and terfenadine; v) keratolytic agents selected from acetretin, calciprotriene, calcifediol, calcitriol, cholecalciferol, ergocalciferol, etretinate, retinoids, targretin, and tazarotene; w) lipid regulating/hypolipidemic agents selected from atorvastatin, bezafibrate, cerivastatin, ciprofibrate, clofibrate, fenofibrate, fluvastatin, gemfibrozil, hesperetin, lovastatin, pravastatin, probucol, and simvastatin; x) opioid analgesics selected from codeine, dextropropoxyphene, diamorphine, dihydrocodeine, fentanyl, meptazinol, methadone, morphine, nalbuphine and pentazocine; and y) nutraceutical agents selected from calcitriol, carotenes, chrysin,
dihydrotachy sterol, flavonoids, hesperitin, jasmonates, lipoic acid, lutein, lycopene, essential fatty acids, non-essential fatty acids, naringenin, phytonadiol, quercetin, vitamins including vitamin A, vitamin B2, vitamin D and derivatives, vitamin E, and vitamin K, coenzyme Q10 (ubiquinone), plant extracts, and minerals.
[94] In some embodiments the at least one active ingredient is selected from the group consisting of flavours, flavour precursors, aromas, aroma precursors, taste enhancers, beeswax, salts, sugars, amino-acids, polysaccharides, enzymes, peptides, proteins or carbohydrates, food supplements, food additives, hormones, bacteria, plant extracts, medicaments, drugs, pharmaceuticals, bio-pharmaceutical, biosimilars, vaccines, viral vectors, antigens, antibodies (Abs), peptibodies, antibody-drug-conjugates (ADCs), nutrients, chemicals for agro-chemical or cosmetic applications, carotenoids, vitamins, antioxidants or nutraceuticals selected from the group comprising of lutein, lutein esters, [beta] -carotene, tocopherol, tocopherol acetate, tocotrienol, lycopene, Co-QlO, flax seed oil, fish oil, omega-3 oils, omega-6 oils, DHA, EPA, arachidonic-rich oils, LCPUFA oils, menthol, mint oil, lipoic acid, vitamins, polyphenols and their glycosides, ester and/or sulphate conjugates, isoflavones, flavonols, flavanones and their glycosides such as hesperidin, flavan 3-ols comprising catechin monomers and their gallate esters such as epigallocatechin gallate and their procyanidin oligomers, vitamin C, vitamin C palmitate, vitamin A, vitamin B12, vitamin D, CC-and [gamma] -polyunsaturated fatty acids, phytosterols, esterified phytosterol, non-esterified phytosterol, zeaxanthine, caffeine and a combination thereof.
[95] The present emulsions are suitable for use in the food industry such as ice-cream sector, mayonnaise sector or margarine sector. As contemplated herein, the term“food industry” includes but is not limited to nutritional, functional and nutraceutical foods. Those of skill in the art would be familiar with the particular food industry requirements and be able to adapt the technical teachings of the present oil-in-water emulsions and methods as needed for the industry. In some embodiments the oil-in-water emulsion comprises food acceptable excipients, additives or ingredients.
[96] In some embodiments there is provided an oil-in-water emulsion for used in the food industry.
[97] In some embodiments there is provided an oil-in-water emulsion for use in making an ice-cream product.
[98] In some embodiments there is provided an oil-in-water emulsion for use in making mayonnaise.
[99] In some embodiments there is provided an oil-in-water emulsion for use in making margarine.
[100] In some embodiments there is provided an oil-in-water emulsion for use in functional foods such as probiotics, pre-biotics and nutraceuticals.
[101] The amount of the active ingredient is higher than 0.00001% of the total weight of the emulsion. Preferably it is higher than 0.00003%, more preferably higher than 0.0001%, and even
more preferably higher than 0.001% of the total weight of the emulsion. The amount of the active ingredient is comprised between 0.00001 and 50 % of the total weight of the emulsion. It is also possible to have an amount of active ingredient comprised between 0.00001 and 40 %. The amount of the active ingredient is lower than 50% of the total weight of the emulsion. Preferably, the amount of active ingredient is lower than 40% of the total weight of the emulsion. Preferably, the amount of active ingredient is lower than 30% of the total weight of the emulsion. Preferably, the amount of active ingredient is lower than 20% of the total weight of the emulsion. Preferably, the amount of active ingredient is lower than 10% of the total weight of the emulsion. Preferably, the amount of active ingredient is lower than 5% of the total weight of the emulsion. Preferably, the amount of active ingredient is lower than 2.5% of the total weight of the emulsion. Preferably, the amount of active ingredient is lower than 2% of the total weight of the emulsion. Preferably, the amount of active ingredient is lower than 1% of the total weight of the emulsion. Any combination of the lower and upper range is comprised in the scope of the present invention. The amount of the active ingredient can be given in wt% or mol% of the total weight or molarity of the emulsion or the total volume of the emulsion.
[102] In some embodiments, the amount of active ingredient is 10% of the total weight of the emulsion. Preferably, the amount of active ingredient is 7.5% of the total weight of the emulsion. Preferably, the amount of active ingredient is 5% of the total weight of the emulsion. Preferably, the amount of active ingredient is 2.5% of the total weight of the emulsion. Preferably, the amount of active ingredient is 1% of the total weight of the emulsion.
[103] As used in the specification and claims, the term“emulsion” refers to the sum of masses of the hydrophilic phase (e.g. water), the lipophilic phase (e.g. oil or triglyceride) and where stated ingredients dissolved therein.
[104] In some embodiments, the substance used for formation of the particles is liquid at room temperature.
[105] In some embodiments, the substance used for formation of the particles is solid at room temperature.
[106] As used herein the term“room temperature” means a comfortable ambient temperature, generally taken as between about 20°C and 25°C (between about 68 and 77°F) with excursions between 10 and 30°C (between about 59 and 86°F) being contemplate, provided the mean kinetic temperature does not exceed 25°C (77°F).
[107] As used in the specification and claims, the term“triglyceride oil” or“triglyceride” refers to esters in which three molecules of one or more different fatty acids are linked to a glycerol. They are named according to the fatty acid components; e.g., tristearin contains three molecules of stearic acid, and oleodistearin, one of oleic acid and two of stearic acid. By way of example triglycerides include at least one of tricaprin (CioTG), trilaurin (CnTG), trimyristin (CMTG), tripalmitin (Ci6TG) and tristearin (CisTG), esters or mixtures thereof. In some embodiments the composition of the present invention comprises at least one of tricaprin (CioTG), trilaurin (CnTG),
trimyristin (CMTG), tripalmitin (C16TG) and tristearin (CisTG) or mixtures thereof. (See Table 1 and Examples). Furthermore, different natural occurring mixtures of triglycerides can be used, for example - coconut oil represents mixture of triglycerides with about 47 % lauric chains, 16 % myristic chains, 10 % palmitic chains, 3% stearic chains, 7% caprylic chains, 8% decanoic chains, 7 % oleic chains and 2 % linoleic chains. The term“triglyceride oil” also include cottonseed oil, flaxseed oil, almond oil, safflower oil, palm oil, sunflower oil, avocado oil, soybean oil, com oil, canola oil, grapeseed oil, rapeseed oil, hazelnut oil, linseed oil, brazil nut oil, peanut oil, rice bran oil, hemp seed oil, olive oil, sesame oil, peanut oil, palm kernel oil, cocoabutter, butter, lard, tallow, medium chain triglyceride oil, long chain triglyceride oil.
Emulsion preparation
[108] Emulsions can be prepared using different known methods.
[109] In some embodiments, hand-shaking of the lipophilic surfactants and the hydrophilic surfactant with the oil component such as triglyceride, can form the initial emulsion.
[110] In some embodiments, the preparation of the initial emulsion is mechanically stirred or injected via applied pressure, e.g. via membrane, valve or capillary.
[111] In some embodiments, the initial emulsion consists of oil drops or droplets, dispersed in water in the presence of at lipophilic surfactant and hydrophilic surfactant and could be prepared by any other method, including membrane emulsification, high pressure homogenization, rotor- stator homogenization, stirred vessels, magnetic or non-magnetic stirring devices (see Examples).
[112] In some embodiments, the initial emulsion consists of oil droplets with different shape and size such as with diameter greater than about 0.5 pm, 1 pm, 2 pm, 3 pm, 4 pm, 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, 10 pm, 20 pm, 30 pm, 40 pm, 50 pm or greater. The oil droplets in the initial emulsion can be of any shape.
[113] In some embodiments, the initial emulsion consists of oil droplets with specific shape and size such as with diameter greater than about 0.5 pm, 1 pm, 2 pm, 3 pm, 4 pm, 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, 10 pm or greater such as 20 pm, 30 pm, 40 pm, 50 pm or greater. The oil droplets in the initial emulsion can be of any shape.
[114] In some embodiments when preparing emulsions with compounds such as active ingredients, which are solid at room temperature, these active ingredients can be melted prior to the initial emulsion formation and maintained at temperature sufficiently high to avoid liquid-solid status transition during emulsification.
[115] In some embodiments, the temperature is not higher than about 10°C relative to the melting point of the selected oil and surfactants.
[116] In some embodiments, the temperature is not higher than about 10°C relative to the melting point of the selected triglyceride and surfactants.
[117] In some embodiments, the temperature is not higher than about 7.5°C relative to the melting point of the selected oil and/or surfactants. In some embodiments, the temperature is not higher than about 7.5°C relative to the melting point of the selected triglyceride and surfactants. In some embodiments, the temperature is not higher than about 5°C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 5°C relative to the melting point of the selected triglyceride and surfactants. In some embodiments, the temperature is not higher than about 2.5°C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 2.5°C relative to the melting point of the selected triglyceride and surfactants. In some embodiments, the temperature is not higher than about 1°C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 1°C relative to the melting point of the selected triglyceride and surfactants. In some embodiments, the temperature is not higher than about 0.5°C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 0.5°C relative to the melting point of the selected triglyceride and surfactants. In some embodiments, the temperature is not higher than about 0.1 °C relative to the melting point of the selected oil and surfactants. In some embodiments, the temperature is not higher than about 0.1 °C relative to the melting point of the selected triglyceride and surfactants.
[118] In some embodiments, the temperature is not higher than about 10°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 10°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 7.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 7.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 2.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 2.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 1°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 1°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 0.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 0.5°C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 0.1 °C relative to the melting point of the selected active ingredient. In some embodiments, the temperature is not higher than about 0.1°C relative to the melting point of the selected active ingredient.
[119] In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is tricaprin (CioTG). In some embodiments there is provided an oil-in-water
emulsion wherein the triglyceride oil is trilaurin (CuTG). In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is trimyristin (C14TG). In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is tripalmitin (C16TG). In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is tristearin (CisTG).
[120] In some embodiments there is provided an oil-in-water emulsion wherein the triglyceride oil is selected from the group consisting of tricaprin (C10TG), trilaurin (CuTG), trimyristin (C14TG), tripalmitin (CieTG) and tristearin (CisTG) or mixtures thereof or mixture of triacylglycerols containing various combinations of CIO, C12, C14, C16 and C18 fatty chains.
[121] In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is between about 0.01% and about 2%, between about 0.025% and about 1.9%, between about 0.05% and about 1.8%, between about 0.1% and about 1.5%, between about 0.15% and about 1.25%, between about 0.2% and about 1%, between about 0.4% and about 0.8% of the total weight of the emulsion, and wherein the concentration of the hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion. In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is 0.7%. In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the lipophilic surfactant is 2.9%.
[122] In some embodiments there is provided an oil-in-water emulsion wherein the concentration of lipophilic surfactant is about 1.5% of the weight of the total emulsion and the concentration of the hydrophilic surfactant is about 1% of the weight of the total emulsion.
[123] In at least one embodiment, the concentration of the lipophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
[124] In at least one embodiment, the concentration of the hydrophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
[125] In some embodiments there is provided an oil-in-water emulsion wherein the lipophilic surfactant is at least one lipophilic surfactant selected from the group consisting of sorbitan monoalkylate (CnSorb) where n is between 12 and 18; polyoxyethylene glycol hexadecyl ether (C16EO2), polyoxyethylene glycol stearyl ether (CigECh), polyethylene glycol monooleyl (Ci8:iE02), oleyl phosphate, oleyl acetate and 1-oleoyl-rac-glycerol (monoolein) or mixtures thereof.
[126] In some embodiments there is provided an oil-in-water emulsion wherein the hydrophilic surfactant is at least one hydrophilic surfactant selected from the group consisting of:
nonionic polyoxyethylene alkyl ether (C„EOm), polyoxyethylene sorbitan monoalkylate (CnSorbEOm) where n is between 12 and 40 and where m is between 20 and 50; polyethylene glycol monooleyl ether (Ci8:iEOm) where m is between 7 and 20; polyoxyethylene octyl phenyl ether; anionic sodium dodecyl sulfate (SDS); sodium lauryl ether sulfate (SLES); cationic surfactant cetyltrimethyl ammonium bromide (CTAB); and cocamidopropyl betaine (CAPB) or mixtures thereof.
[127] In some embodiments there is provided an oil-in-water emulsion wherein the emulsion is exposed to or treated to at least two cooling-heating cycles, at least three cooling-heating cycles, at least four cooling-heating cycles, at least five cooling-heating cycles, at least six cooling-heating cycles, at least seven cooling-heating cycles, at least eight cooling-heating cycles or more coolingheating cycles.
[128] The order in which the emulsions of the present invention are treated can be varied depending on the constituents of the emulsions which have been selected. In some embodiments the emulsion or any of the constituents can be exposed to cooling before heating. In some embodiments the emulsion or any of the constituents can be exposed to heating before cooling.
[129] The time or duration of heating of the emulsion can be varied depending on the constituents of the emulsions which have been selected. In some embodiments the emulsion or constituents of the emulsion can be exposed to heating for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40 or 50 seconds; 1, 2, 5, 10, 15, 20, 30, 40, 50, 60 minutes; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours or more.
[130] The time or duration of cooling of the emulsion can be varied depending on the constituents of the emulsions which have been selected. In some embodiments the emulsion or constituents of the emulsion can be exposed to cooling for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40 or 50 seconds; 1, 2, 5, 10, 15, 20, 30, 40, 50, 60 minutes; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours or more.
[131] As used herein, the terms“cooling”,“freezing”,“re-cooling” and“re-freezing” are used interchangeably unless specifically stated otherwise or the context of the term dictates differently. In some embodiments of the method of the present invention, the cooling or freezing temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C below the cooling or freezing temperature of the oil.
[132] As used herein, the terms“heating”,“melting”,“re-heating” and“re-melting” are used interchangeably unless specifically stated otherwise or the context of the term dictates differently. In some embodiments of the method of the present invention, the heating or melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the heating or melting temperature of the oil.
[133] In some embodiments, the melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C above the heating or melting temperature of the triglyceride oil.
[134] In some embodiments, the melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C above the melting temperature of tricaprin (CioTG), trilaurin (CnTG), trimyristin (CMTG), tripalmitin (Ci6TG) and tristearin (CisTG) or mixtures thereof.
[135] In some embodiments, the freezing temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C below the freezing temperature of tricaprin (CioTG), trilaurin (CnTG), trimyristin (CMTG), tripalmitin (CMTG) and tristearin (CisTG) or mixtures thereof.
[136] In some embodiments there is provided an oil-in-water emulsion wherein the nanosized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised with at least one lipophilic surfactant and at least one hydrophilic surfactant. In some embodiment, there is provided an emulsion comprising stabilised nano-sized self-emulsified particulates have a diameter of between about 12 nm to about 480 nm, about 14 nm to about 460 nm, about 16 nm to about 440 nm, about 18 nm to about 420 nm, about 20 nm to about 400 nm, about 22 nm to about 380 nm, about 24 nm to about 360 nm, about 26 nm to about 340 nm, about 28 nm to about 320 nm, 30 nm to about 300nm, about 35 nm to about 280 nm, about 40 nm of about 260nm, about 45 nm to about 240 nm, about 50 nm to about 220, about 55 nm to about 200, about 60 nm to about 180 nm, about 65 nm to about 160 nm, about 70 nm to about 140 nm, about 75 nm to about 120 nm, about 80 nm to about 100 nm.
[137] In some embodiments, there is provided an oil-in-water emulsion wherein the nanosized self-emulsified particulates with a diameter of about 20 nm.
[138] In some embodiments there is provided an oil-in-water emulsion wherein the centration of the stabilising lipophilic surfactant is between about 0.01% and about 2%, between about 0.025% and about 1.9%, between about 0.05% and about 1.8%, between about 0.1% and about 1.5%, between about 0.15% and about 1.25%, between about 0.2% and about 1%, between about 0.4% and about 0.8% of the total weight of the emulsion, and wherein the concentration of the stabilising hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion. In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the stabilising lipophilic surfactant is 0.7%. In some embodiments there is provided an oil-in-water emulsion wherein the concentration of the stabilising lipophilic surfactant is 2.9%.
[139] In at least one embodiment, the concentration of the stabilising lipophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
[140] In at least one embodiment, the concentration of the stabilising hydrophilic surfactant is higher than about 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% for example higher than 12 % and specifically up to 20 % of the weight of the total emulsion.
[141] In some embodiments there is provided an oil-in-water emulsion wherein the cooling rate of the cooling-heating cycle is between about 0.01 K min 1 and about 1000 K min 1, between about 0.01 K min 1 and about 50 K min 1, between about 0.025 K min 1 and about 45 K min 1, between about 0.05 K min 1 and about 40 K min 1, between about 0.075 K min 1 and about 35 K min 1, between about 0.1 K min 1 and about 30 K min 1, between about 0.125 K min 1 and about 25 K min 1, between about 0.2 K min 1 and about 20 K min 1, between about 0.4 K min 1 and about 15 K min 1, between about 0.5 K min 1 and about 10 K min 1, between about 0.75 K min 1 and about
7.5 K min 1, between about 1 K min 1 and about 5 K min 1, between about 1.25 K min 1 and about
2.5 K min 1, between about 1.5 K min 1 and about 2 K min 1. In some embodiments the cooling rate is about 1 K min 1.
[142] In some embodiments there is provided an oil-in-water emulsion wherein the heating rate of the cooling-heating cycle is between about 0.01 K min 1 and about 10 K min 1, between about 0.025 K min 1 and about 9.5 K min 1, between about 0.05 K min 1 and about 9 K min 1, between about 0.075 K min 1 and about 8.5 K min 1, between about 0.1 K min 1 and about 8 K min 1, between about 0.125 K min 1 and about 7.5 K min 1, between about 0.2 K min 1 and about 7 K min 1, between about 0.4 K min 1 and about 6.5 K min 1, between about 0.5 K min 1 and about 6 K min 1, between about 0.75 K min 1 and about 5.5 K min 1, between about 1 K min 1 and about 5 K min 1, between about 1.25 K min 1 and about 4.5 K min 1, between about 1.5 K min 1 and about 4 K min 1, between about 2 K min 1 and about 3 K min 1. In some embodiments, the heating rate of the cooling-heating cycle is about 1 K min 1.
[143] In some embodiments there is provided an oil-in-water emulsion comprising mixtures of triglycerides. In some embodiments the triglyceride is at least one selected from the group consisting of tripalmitin, trimyristin, trilaurin, coconut oil or other vegetable oil. In some embodiments the coconut oil is a mixture of triglycerides with about 47 % lauric chains, 16 % myristic chains, 10 % palmitic chains, 3% stearic chains, 7% caprylic chains, 8% decanoic chains, 7 % oleic chains and 2 % linoleic chains. In some embodiments the triglyceride oil can be selected from cottonseed oil, flaxseed oil, almond oil, safflower oil, palm oil, sunflower oil, avocado oil, soybean oil, com oil, canola oil, grapeseed oil, rapeseed oil, hazelnut oil, linseed oil, brazil nut oil, peanut oil, rice bran oil, hemp seed oil, olive oil, sesame oil, peanut oil, palm kernel oil, cocoa butter, butter, lard, tallow, medium chain triglyceride oil, long chain triglyceride oil.
[144] In some embodiments, an oil-in-water emulsion containing mixtures of other oils, such as diglycerides (diacylglycerols), mono-glycerides (monoacylglycerols), phospholipids, lysolipids. In some embodiments, such mixtures are used as lipid drug delivery systems.
[145] In some embodiments the oil in the oil-in-water emulsion is an excipient for dissolving, dispersing, or otherwise delivering an active compound, though the oil can be an active ingredient itself.
[146] In some embodiments there is provided an oil-in-water emulsion wherein the active ingredient is at least one selected from the group consisting of flavours, flavour precursors, aromas, aroma precursors, taste enhancers, salts, sugars, amino-acids, polysaccharides, enzymes, peptides, proteins or carbohydrates, food supplements, food additives, hormones, bacteria, plant extracts, medicaments, drugs, pharmaceuticals, bio-pharmaceutical, biosimilars, vaccines, antigens, antibodies (Abs), peptibodies, antibody-drug-conjugates (ADCs), nutrients, chemicals for agrochemical or cosmetic applications, carotenoids, vitamins, antioxidants or nutraceuticals selected from the group comprising of lutein, lutein esters, [beta] -carotene, tocopherol, tocopherol acetate, tocotrienol, lycopene, Co-QlO, flax seed oil, fish oil, omega-3 oils, omega-6 oils, DHA, EPA, arachidonic-rich oils, LCPUFA oils, menthol, mint oil, lipoic acid, vitamins, polyphenols and their glycosides, ester and/or sulphate conjugates, isoflavones, flavonols, flavanones and their glycosides such as hesperidin, flavan 3-ols comprising catechin monomers and their gallate esters such as epigallocatechin gallate and their procyanidin oligomers, vitamin C, vitamin C palmitate, vitamin A, vitamin B12, vitamin D, CC-and [gamma] -polyunsaturated fatty acids, phytosterols, esterified phytosterol, non-esterified phytosterol, zeaxanthine, caffeine and a combination thereof.
[147] In some embodiments there is provided an oil-in-water emulsion wherein the emulsion is dried in a powder form. By way of example only, small angle X-ray scattering and Cryo-TEM can show that active ingredients and structure of the particulates of oil-in-water emulsion of the invention is reconstituted when the dried emulsion is reconstituted by addition of water.
[148] In some embodiments there is provided an oil-in-water emulsion wherein the emulsion is a starting material, an intermediate product or an additive to a final product.
[149] In some embodiments there is provided an oil-in-water emulsion wherein the starting material, the intermediate product or additive to a final product is a pharmaceutical, agro-chemical, consumer, food supplement or cosmetic starting material, the intermediate product or additive to a final product.
[150] In some embodiments there is provided an oil-in-water emulsion wherein the starting material, the intermediate product or additive to a final product has an increased shelf-life.
[151] In some embodiments there is provided an oil-in-water emulsion for use in enhancing stability, protection against chemical or enzymatic degradation or oxidation of an active ingredient in the oil-in-water emulsion.
[152] In some embodiments there is provided an oil-in-water emulsion for use in enhancing bioavailability, bioaccessibility or absorption of active ingredient during digestion.
[153] In some embodiments there is provided an oil-in-water emulsion for use in controlled release, burst release, or sustained release of an active ingredient during consumption or digestion.
[154] In some embodiments there is provided an oil-in-water emulsion for use in controlled release of aroma or flavour, burst release of aroma or flavour, or sustained release of aroma or flavour to create new or improved sensory or taste properties.
[155] In some embodiments there is provided an oil-in-water emulsion for use in creating different taste, different texture, mouth feel, mouth coating, or creaminess sensation.
[156] In some embodiments there is provided an oil-in-water emulsion for use in taste masking, off taste masking, flavour masking, off flavour masking, taste modulation or flavour modulation.
[157] Here we also disclose in one aspect a pharmaceutical combination comprising the oil- in-water emulsion of the present invention and at least one further pharmaceutically acceptable surfactant, excipient or additive.
[158] In some embodiments the pharmaceutical combination comprises the oil-in-water emulsion of the present invention and at least one or more pharmaceutically acceptable excipients or additive.
[159] As used herein, a "pharmaceutically acceptable excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatine, vegetable oils and polyethylene glycols.
[160] In some embodiments the pharmaceutical combination comprises a therapeutically active ingredient. In some embodiments the therapeutically active ingredient is an anti-cancer agent. In some embodiments the anti-cancer agent is a chemotherapy agent. In some embodiments the anti-cancer agent is a biotherapeutic agent such as an antibody (Ab) or a functional derivative of an Ab. In some embodiments the active ingredient is an antimicrobial agent. In some embodiments the antimicrobial agent is an antibacterial agent such as an antibiotic.
[161] In some embodiments there is provided a pharmaceutical combination for use in medicine.
[162] Here we also describe a low-energy method which leads to oil-in-water nanoemulsions, containing particulates with a diameter range between about 10 nm to about 500 nm. The method requires a combination of hydrophilic surfactants and lipophilic surfactants and controlled variation of the emulsion temperature around melting temperature of the oil. In some embodiments, the melting temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C above the melting temperature of the oil.
[163] In some embodiments, the freezing temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C below the freezing temperature of the oil.
[164] According to one aspect of the present invention, there is provided a method for producing an oil-in-water emulsion according to the present invention, wherein the method comprising the steps of:
a. preparing an initial emulsion of a lipophilic phase in a hydrophilic phase to form oil droplets of a diameter greater than 1 pm in the presence of at least one lipophilic surfactant and at least one hydrophilic surfactant; and b. treating the initial emulsion to form an oil-in-water emulsion comprising nano-sized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm.
[165] In some embodiments of the method of the present invention, wherein the initial emulsion comprises an intermediate metastable phase.
[166] In some embodiments of the method of the present invention, the initial emulsion is subjected to at least one cooling cycle.
[167] In some embodiments of the method of the present invention, the oil is selected from the group consisting of vegetable oils, triglyceride oils, essential oils, flavouring oils, esters, alkanes, paraffins, waxes, diglycerides, phospholipids and mixtures thereof.
[168] In some embodiments of the method of the present invention, the oil is triglyceride oil.
[169] In some embodiments of the present invention, the method requires usage of hydrophilic and/or lipophilic surfactant and controlled variation of the emulsion temperature around the cooling-heating or melting-freezing temperature of the triglyceride.
[170] In some embodiments of the method of the present invention, the initial emulsion is treated by at least two cooling-heating cycles, at least three cooling-heating cycles, at least four cooling-heating cycles, at least five cooling-heating cycles, at least six cooling-heating cycles, at least seven cooling-heating cycles, at least eight cooling-heating cycles or more cooling-heating cycles.
[171] In some embodiments of the method of the present invention, the heating temperature is not more than about 10°C, 9°C, 8°C, 7°C, 6°C, 5°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1 °C above the melting temperature of the triglyceride.
[172] In some embodiments of the method of the present invention, the cooling temperature is not more than about 100°C, 90°C, 80°C, 70°C, 60°C, 50°C, 40°C, 30°C, 20°C, 10°C, 4.5°C, 4°C, 3.5°C, 3°C, 2.5°C, 2°C, 1.5°C, 1°C, 0.5°C, 0.25°C, 0.15°C, 0.1°C below the freezing temperature of the triglyceride.
[173] In some embodiments of the method of the present invention, the nano-sized self- emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised. In some embodiments of the method of the present invention, the stabilised nano-sized self- emulsified particulates have a diameter of between about 12 nm to about 280 nm, about 14 nm to about 260 nm, about 16 nm to about 240 nm, about 18 nm to about 220 nm, about 20 nm to about 200 nm, about 22 nm to about 180 nm, about 24 nm to about 160 nm, about 26 nm to about 140 nm, about 28 nm to about 120 nm, 30 nm to about lOOnm, about 35 nm to about 80 nm, about 40 nm of about 70 nm, about 45 nm to about 65 nm. In some embodiments, of the method of the
present invention, the stabilised nano-sized self-emulsified particulates have a diameter of about 20 nm.
[174] In some embodiments of the method of the present invention, the cooling rate is between about 0.01 K min 1 and about 1000 K min 1, between about 0.01 K min 1 and about 50 K min 1, between about 0.025 K min 1 and about 45 K min 1, between about 0.05 K min 1 and about 40 K min 1, between about 0.075 K min 1 and about 35 K min 1, between about 0.1 K min 1 and about 30 K min 1, between about 0.125 K min 1 and about 25 K min 1, between about 0.2 K min 1 and about 20 K min 1, between about 0.4 K min 1 and about 15 K min 1, between about 0.5 K min 1 and about 10 K min 1, between about 0.75 K min 1 and about 7.5 K min 1, between about 1 K min 1 and about 5 K min 1, between about 1.25 K min 1 and about 2.5 K min 1, between about 1.5 K min 1 and about 2 K min 1. In some embodiments the cooling rate is about 1 K min 1.
[175] In some embodiments of the method of the present invention, the heating rate is between about 0.01 K min 1 and about 10 K min 1, between about 0.025 K min 1 and about 9.5 K min 1, between about 0.05 K min 1 and about 9 K min 1, between about 0.075 K min 1 and about 8.5 K min 1, between about 0.1 K min 1 and about 8 K min 1, between about 0.125 K min 1 and about 7.5 K min 1, between about 0.2 K min 1 and about 7 K min 1, between about 0.4 K min 1 and about 6.5 K min 1, between about 0.5 K min 1 and about 6 K min 1, between about 0.75 K min 1 and about 5.5 K min 1, between about 1 K min 1 and about 5 K min 1, between about 1.25 K min 1 and about 4.5 K min 1, between about 1.5 K min 1 and about 4 K min 1, between about 2 K min 1 and about 3 K min 1. In some embodiments, the heating rate of the cooling-heating cycle is about 1 K min 1.
[176] In order that the invention may be readily understood and put into practical effect, particular embodiments will now be described by way of the following non-limiting examples.
EXAMPLES
[177] Triglycerides used in the current invention are purchased from TCI, Alfa Aesar or Sigma-Aldrich and have analytical purity, > 80%, see Table 1. The surfactants used are presented in Table 2.
[178] After emulsion preparation, samples were placed in glass capillaries - 50 mm long, 1 or 2 mm wide and 0.10 mm high. The capillaries were put in a thermostated vessel, consisting of a metal plate with water circulating through it. The vessel is connected to a cryo-thermostate (Julabo CF30), allowing high precision temperature control (accuracy ± 0.2 °C).
[179] During the cooling/heating of the emulsions a microscope AxioImager.M2m (Zeiss, Germany) was used in transmitted white, polarized light. The microscopes were equipped with l plate, set at 45° in between the analyzer and the polarizer. The observations were held by the means of long-distance objective with 20x, 5 Ox or lOOx (x = times) magnification. The size of the drops
and particles was determined from the microscopic images in which the drops had diameter > 1 pm. The mean volume-surface diameter was determined from the relation:
[180] For determination of the drop sizes in samples with drops smaller than 1 pm the dynamic light scattering method was used. These measurements were performed at 30 °C with 4700C system (Malvern Instruments, U.K.), equipped with a solid state laser, operating at 514 nm. Multimodal software was used for analysis of the autocorrelation function of the light scattered by the emulsion.
[181] Table 1. List of the triglycerides used. The values for melting points are stated as provided by the producers.
[183] This example demonstrates the drop-size decrease, illustrated in Figure 1 (a) and (b). 1.5 wt. % Brij S20 and 1 wt. % monopalmitin and monostearin mixture is dispersed in water. CMTG is added to the aqueous phase through membrane emulsification. The triglyceride volume fraction in the prepared emulsion is 0.7 vol. %. The initial drop or droplet size in the prepared emulsion is 20 pm (Figure 1(a)) or 33.5 pm (Figure 1(b)). The emulsion is cooled from 335 K to 278 K in a fridge and then heated back up to 335 K in a water bath - where only the lipid component of the emulsion is solidified. After two consecutive freeze-thaw cycles the drop diameter by volume become 100 nm and after 4 freeze-thaw cycles, it becomes 20 nm. This drop diameter does not change if more freeze-thaw cycles are performed. Depending on the final temperature, the droplets could be liquid or solid.
[184] Figure 1(a) Illustrates the drop-size decrease observed with large scale or bulk emulsions. The smallest drop diameter which is reached after 4 consecutive freeze/thaw cycles for emulsion with 0.7 vol. % oil and drops with initial diameter around 20 pm is 20 nm. The emulsion is prepared with CMTG and stabilized by 1.5 wt.% CigEC o and 1 wt.% monopalmitin and monostearin mixture, dispersed in the aqueous phase.
[185] Figure 1(b) Illustrates the drop size decrease observed with large scale or bulk emulsions. The smallest drop or droplet diameter which is reached after 4 consecutive freeze/thaw cycles for emulsion with 2.9 vol. % oil and drops with initial diameter around 33.5 pm is 40 nm. The emulsion is prepared with CMTG and stabilized by 1.5 wt.% CigEC o and 1 wt.% monopalmitin and monostearin mixture, dispersed in the aqueous phase.
[186] Example 2 Preparation of nanoemulsion without freeze-thaw cycling of the emulsion
[187] This example demonstrates the drop-size decrease observed in emulsions which are stored at 35°C without heating and/or additional cooling. The initial emulsion is prepared by membrane emulsification and drops or droplet have initial diameter of 35 pm. Emulsion contains 2.9 vol. % emulsified CMTG and water phase containing 1.5 wt. % Brij S20 and 1 wt. % monopalmitin and monostearin mixture. The emulsion drops are prepared at temperature of 335 K. After the initial preparation, the emulsion is placed in a glass capillary which is sealed and stored at 35°C. The emulsion is observed under a microscope upon different periods of storage, see Figure 2. Drop disintegration upon storage is observed. The particles that form upon the disintegration have diameter smaller than 1 pm.
[188] Figure 2 Depicts the particle disintegration observed upon storage of the emulsion. Particle disintegration observed with CMTG sample stored at 35°C. After 19 h at 35°C, the particle volume noticeably increased and the disintegration process has already begun. After 67 h, significant fraction of the particles has already disintegrated. The reason for the lower contrast of this image is the appearance of numerous small droplets which scatter the light illuminating the
sample. These observations are performed in a glass capillary which was stored in a thermostat at 35°C and was observed at certain time intervals, as indicated in the images.
[189] The disclosure illustratively described herein can suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms“comprising”,“including,” containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the disclosure claimed.
* * *
References:
1. Kentish S., Wooster T.J., Ashokkumar M., Balachandran S., Mawson R., Simons L. The use of ultrasonics for nanoemulsions preparation. Innovative Food Sci. Emerging Technol, 2008; 9:170-175. doi: 10.1016/j.ifset.2007.07.005
2. Wooster T., Golding M., Sanguansri P. Impact of oil type on nanoemulsion formation and Ostwald ripening stability. Langmuir, 2008; 24:12758-12765. doi: 10.1021/la801685v
3. Zhu Z., Wen Y., Yi J., Cao Y., Liu F., McClements D.J. Comparison of natural and synthetic surfactants at forming and stabilizing nanoemulsions: Tea saponin, Quillaja saponin, and Tween 80. J Colloid Interface Sci., 2019; 536:80-87. doi: 10.1016/j.jcis.2018.10.024
4. Tcholakova S., Denkov, N., Ivanov L, Campbell B. Coalescence stability of emulsions containing globular milk proteins. Adv. Colloid Interface Sci., 2006; 123-126:259-293
5. P.S. Denkova, S. Tcholakova, N.D. Denkov, K. D. Danov, B. Campbell, C. Shawl, D. Kim, Evaluation of the Precision of Drop-Size Determination in Oil/Water Emulsions by Low- Resolution NMR Spectroscopy. Langmuir 20 (2004) 11402-11413
6. P. A. Kralchevsky, K. D. Danov and N. D. Denkov, Chemical Physics of Colloid Systems and Interfaces. Chapter 7 in Handbook of Surface and Colloid Chemistry (3rd Updated Edition; K. S. Birdi, Ed.). CRC Press, Boca Raton, FL, 2008.
Claims
1. Oil-in-water emulsion wherein oil droplets of a diameter greater than 1 pm exhibit nano-sized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm, due to the presence of:
a. at least one lipophilic surfactant; and/or
b. at least one hydrophilic surfactant.
2. Oil-in- water emulsion according to claim 1, wherein the oil-in- water emulsion comprises one or more active ingredients.
3. Oil-in- water emulsion according to claim 2, wherein the active ingredient is lipophilic.
4. Oil-in- water emulsion according to any one of claims 2 or 3, wherein the active ingredient is between 0.0001% and 50% of the total weight of the emulsion.
5. Oil-in- water emulsion according to any one of the preceding claims, wherein the emulsion comprises oil droplets having nano-sized self-emulsified particulates comprising:
i) oil selected from the group consisting of vegetable oils, triglyceride oils, essential oils, flavouring oils, esters, alkanes, paraffins, waxes, diglycerides, phospholipids and mixtures thereof;
ii) at least one lipophilic surfactant with HLB value (Hydrophilic-Lipophilic Balance) < 10 and/or at least one hydrophilic surfactant, having HLB > 10.
6. Oil-in-water emulsion according to claim 5, wherein the oil is a triglyceride oil.
7. Oil-in-water emulsion according to claim 5 or claim 6, wherein the triglyceride oil is selected from the group consisting of tricaprin (CioTG), trilaurin (C12TG), trimyristin (C14TG), tripalmitin (C16TG) and tristearin (CixTG) or mixtures thereof.
8. Oil-in- water emulsion according to any one of claims 1 to 7, wherein for 1% oil content in the emulsion the preferred concentration of the lipophilic surfactant is between about 0.01% and about 3%, between about 0.025% and about 2.8%, between about 0.05% and about 2.6%, between about 0.1% and about 2.4%, between about 0.2% and about 2%, between about 0.4% and about 2%, between about 0.8% and about 1.8% of the total weight of the emulsion, and wherein the concentration of the hydrophilic surfactant is between about 0.1% and about 5%, between 0.2% and about 4.5%, between about 0.3% and about 4%, between about 0.4 and about 3.5%, between about 0.5% and about 3%, between about 0.6% and about 2.5%, between about 0.7% and about 2%, between about 0.8% and about 1.5%, between about 0.9% and about 1% of the weight of the total emulsion.
9. Oil-in-water emulsion according to claim 8, wherein the concentration of the lipophilic surfactant is about 1.5% of the weight of the total emulsion and the concentration of the hydrophilic surfactant is about 1% of the weight of the total emulsion.
10. Oil-in- water emulsion according to anyone of claim 1 to 9, wherein the lipophilic surfactant is at least one lipophilic surfactant selected from the group consisting of sorbitan monoalkylate (CnSorb) where n is between 12 and 18; polyoxyethylene glycol hexadecyl ether (C16EO2), polyoxyethylene glycol stearyl ether (C18EO2), polyethylene glycol monooleyl (Ci8:iE02), oleyl phosphate, oleyl acetate and 1-oleoyl-raoglycerol (monoolein).
11. Oil-in- water emulsion according to claims 1 to 10, wherein the hydrophilic surfactant is at least one hydrophilic surfactant selected from the group consisting of: nonionic polyoxyethylene alkyl ether (C„EOm), polyoxyethylene sorbitan monoalkylate (CnSorbEOm) where n is between 12 and 40 and where m is between 20 and 50; polyethylene glycol monooleyl ether (CisuEOm) where m is between 7 and 20; polyoxyethylene octyl phenyl ether; anionic sodium dodecyl sulfate (SDS); sodium lauryl ether sulfate (SLES); cationic surfactant cetyltrimethyl ammonium bromide (CTAB); and cocamidopropyl betaine (CAPB).
12. Oil-in- water emulsion according to any one of claims 1 to 11, wherein the emulsion is exposed to at least two cooling-heating cycles.
13. Oil-in- water emulsion according to any one of claims 1 to 12, wherein the nano-sized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised with at least one lipophilic surfactant and at least one hydrophilic surfactant.
14. Oil-in- water emulsion according to claim 13, wherein the stabilised nano-sized self- emulsified particulates have a diameter of about 20 nm to 50 nm.
15. Oil-in- water emulsion according to any one of claims 13 or 14, wherein the concentration of the stabilising lipophilic surfactant is between about 0.01% and about 2%.
16. Oil-in-water emulsion according to any one of claims 12 to 15, wherein the cooling rate of the cooling-heating cycle is between about 0.01 K min 1 and about 1000 K min 1, between about 0.025 K min 1 and about 50 K min 1, between about 0.05 K min 1 and about 40 K min 1, between about 0.075 K min 1 and about 35 K min 1, between about 0.1 K min 1 and about 30 K min 1, between about 0.125 K min 1 and about 25 K min 1, between about 0.2 K min 1 and about 20 K min 1, between about 0.4 K min 1 and about 15 K min 1, between about 0.5 K min 1 and about 10 K min 1, between about 0.75 K min 1 and about 7.5 K min 1, between about 1 K min 1 and about 5 K min 1, between about 1.25 K min 1 and about 2.5 K min 1, between about 1.5 K min 1 and about 2 K min 1.
17. Oil-in- water emulsion according to any one of claims 12 to 15, wherein the heating rate of the cooling-heating cycle is between about 0.01 K min 1 and about 1000 K min 1.
18. Oil-in-water emulsion according to any one of claims 1 to 17, wherein the emulsion comprises trimyristine, C18EO20 and Ci8:iE02.
19. Oil-in- water emulsion according to any one of claims 2 to 18, wherein the active ingredient is at least one selected from the group consisting of flavours, flavour precursors, aromas, aroma precursors, taste enhancers, beeswax, salts, sugars, amino- acids, polysaccharides, enzymes, peptides, proteins or carbohydrates, food supplements, food additives, hormones, bacteria, plant extracts, medicaments, drugs, pharmaceuticals, antineoplastics (including curcumin and cannabinoids), psychoactives, steroids and modified steroids, sterols (including cholesterol), bio- pharmaceutical, constrained peptides, biosimilars, vaccines, antigens, antibodies (Abs), peptibodies, antibody-drug-conjugates (ADCs), nutrients, chemicals for agro chemicals (including terpenes), chemicals for cosmetic applications, carotenoids, vitamins, antioxidants or nutraceuticals selected from the group comprising of lutein, lutein esters, [beta]-carotene, tocopherol, tocopherol acetate, tocotrienol, lycopene, Co- Q10, flax seed oil, fish oil, omega-3 oils, omega-6 oils, DHA, EPA, arachidonic-rich oils, LCPUFA oils, menthol, mint oil, lipoic acid, vitamins, polyphenols and their glycosides, ester and/or sulphate conjugates, isoflavones, flavonols, flavanones and their glycosides such as hesperidin, flavan 3-ols comprising catechin monomers and their gallate esters such as epigallocatechin gallate and their procyanidin oligomers, vitamin C, vitamin C palmitate, vitamin A, vitamin B 12, vitamin D, CC-and [gamma] - polyunsaturated fatty acids, phytosterols, esterified phytosterol, non-esterified phytosterol, zeaxanthine, caffeine and a combination thereof.
20. Powder and/or lipid nanoparticles wherein the oil-in-water emulsion according to any one of claims 1 to 19 is stabilized and dried in a powder form.
21. Oil-in- water emulsion according to any one of claims 1 to 19, wherein the emulsion is a final product, a starting material, an intermediate product or an additive to a final product.
22. Oil-in- water emulsion according to claim 21 wherein the starting material, the intermediate product or additive to a final product is a pharmaceutical, agro-chemical, consumer, food supplement or cosmetic starting material, the intermediate product or additive to a final product.
23. Oil-in- water emulsion according to any one of claims 1 to 19 for use in enhancing stability, protection against chemical or enzymatic degradation or oxidation of an active ingredient in the oil-in-water emulsion.
24. Oil-in- water emulsion according to any of claims 1 to 19 for use in enhancing bioavailability, bioaccessibility, absorption of active ingredient during digestion,
controlled release, burst release, or sustained release of an active ingredient during consumption or digestion.
25. Oil-in- water emulsion according to any one of claims 1 to 19 for use in controlled release of aroma or flavour, burst release of aroma or flavour, or sustained release of aroma or flavour to create new or improved sensory or taste properties.
26. Oil-in- water emulsion according to any one of claims 1 to 19 for use for creating different taste, different texture, mouth feel, mouth coating, or creaminess sensation.
27. Oil-in- water emulsion according to any one of claims 1 to 19 for use in taste masking, off taste masking, flavour masking, off flavour masking, taste modulation or flavour modulation.
28. A pharmaceutical combination comprising the oil-in-water emulsion according to any one of claims 1 to 19 and at least one further pharmaceutically acceptable surfactant, excipient or additive.
29. Oil-in- water emulsion according to any one of claims 1 to 19 or a pharmaceutical combination according to claim 28, for use in medicine.
30. A method for producing an oil-in- water emulsion according to any one of claims 1 to 19, the method comprising the steps of:
a. preparing an initial emulsion of a lipophilic phase in a hydrophilic phase to form oil droplets of a diameter greater than 1 pm in the presence of at least one lipophilic surfactant and/or at least one hydrophilic surfactant; and
b. cooling and/or heating the initial emulsion to form an oil-in-water emulsion comprising nano-sized self-emulsified particulates with a diameter in the range of about 10 nm to about 500 nm.
31. A method according to claim 30, wherein the mixture is exposed to at least two cooling- heating cycles.
32. A method according to anyone of claims 30 or 31, wherein the nano-sized self- emulsified particulates with a diameter in the range of about 10 nm to about 500 nm are stabilised and/or dried in a powder form.
A method according to claim 32, wherein the stabilised nano-sized self-emulsified particulates have a diameter of about 20 nm to 50 nm.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1909358.2A GB201909358D0 (en) | 2019-06-28 | 2019-06-28 | Oil-in-water emulsion of nano-sized self-emulsified particulates |
GB1909358.2 | 2019-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020260577A1 true WO2020260577A1 (en) | 2020-12-30 |
Family
ID=67539983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2020/068018 WO2020260577A1 (en) | 2019-06-28 | 2020-06-26 | Oil-in-water emulsion of nano-sized self-emulsified particulates |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201909358D0 (en) |
WO (1) | WO2020260577A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112773776A (en) * | 2019-11-11 | 2021-05-11 | 上海胜联医药科技有限公司 | Drug-loaded nanoparticle system |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0696452A1 (en) * | 1994-08-08 | 1996-02-14 | Laboratorios Cusi, S.A. | Nanoemulsion of the oil in water type, useful as an ophthalmic vehicle and process for the preparation thereof |
EP1598060A1 (en) * | 2004-05-18 | 2005-11-23 | Nestec S.A. | Oil-in-water emulsion for delivery |
WO2007060177A1 (en) * | 2005-11-22 | 2007-05-31 | Nestec S.A. | Oil-in-water emulsion and its use for the delivery of functionality |
WO2020018512A1 (en) * | 2018-07-19 | 2020-01-23 | Nanogen Lab, Inc. | Nanoemulsion hydrophobic substances |
-
2019
- 2019-06-28 GB GBGB1909358.2A patent/GB201909358D0/en not_active Ceased
-
2020
- 2020-06-26 WO PCT/EP2020/068018 patent/WO2020260577A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0696452A1 (en) * | 1994-08-08 | 1996-02-14 | Laboratorios Cusi, S.A. | Nanoemulsion of the oil in water type, useful as an ophthalmic vehicle and process for the preparation thereof |
EP1598060A1 (en) * | 2004-05-18 | 2005-11-23 | Nestec S.A. | Oil-in-water emulsion for delivery |
WO2007060177A1 (en) * | 2005-11-22 | 2007-05-31 | Nestec S.A. | Oil-in-water emulsion and its use for the delivery of functionality |
WO2020018512A1 (en) * | 2018-07-19 | 2020-01-23 | Nanogen Lab, Inc. | Nanoemulsion hydrophobic substances |
Non-Patent Citations (6)
Title |
---|
KENTISH S.WOOSTER T.J.ASHOKKUMAR M.BALACHANDRAN S.MAWSON R.SIMONS L.: "The use of ultrasonics for nanoemulsions preparation", INNOVATIVE FOOD SCI. EMERGING TECHNOL., vol. 9, 2008, pages 170 - 175, XP002540746, DOI: 10.1016/j.ifset.2007.07.005 |
P. A. KRALCHEVSKYK. D. DANOVN. D. DENKOV: "Handbook of Surface and Colloid Chemistry", 2008, CRC PRESS, article "Chemical Physics of Colloid Systems and Interfaces" |
P.S. DENKOVAS. TCHOLAKOVAN.D. DENKOVK. D. DANOVB. CAMPBELLC. SHAWLD. KIM: "Evaluation of the Precision of Drop-Size Determination in Oil/Water Emulsions by Low-Resolution NMR Spectroscopy", LANGMUIR, vol. 20, 2004, pages 11402 - 11413 |
TCHOLAKOVA S.DENKOV, N.IVANOV I.CAMPBELL B.: "Coalescence stability of emulsions containing globular milk proteins", ADV. COLLOID INTERFACE SCI., vol. 123-126, 2006, pages 259 - 293, XP025061752, DOI: 10.1016/j.cis.2006.05.021 |
WOOSTER T.GOLDING M.SANGUANSRI P.: "Impact of oil type on nanoemulsion formation and Ostwald ripening stability", LANGMUIR, vol. 24, 2008, pages 12758 - 12765 |
ZHU Z.WEN Y.YI J.CAO Y.LIU F.MCCLEMENTS D.J.: "Comparison of natural and synthetic surfactants at forming and stabilizing nanoemulsions: Tea saponin, Quillaja saponin, and Tween 80", J. COLLOID INTERFACE SCI., vol. 536, 2019, pages 80 - 87, XP085544635, DOI: 10.1016/j.jcis.2018.10.024 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112773776A (en) * | 2019-11-11 | 2021-05-11 | 上海胜联医药科技有限公司 | Drug-loaded nanoparticle system |
Also Published As
Publication number | Publication date |
---|---|
GB201909358D0 (en) | 2019-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McClements | Advances in nanoparticle and microparticle delivery systems for increasing the dispersibility, stability, and bioactivity of phytochemicals | |
JP6799504B2 (en) | PH-dependent carriers for targeted release of drugs along the gastrointestinal tract, compositions thereof, and their manufacture and use. | |
de Abreu Figueiredo et al. | Microencapsulation by spray chilling in the food industry: Opportunities, challenges, and innovations | |
Tenorio-Garcia et al. | Recent advances in design and stability of double emulsions: Trends in Pickering stabilization | |
WO2008053920A1 (en) | Physiologically active substance-containing granular composition and method of producing the same | |
Tang et al. | Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as food-grade nanovehicles for hydrophobic nutraceuticals or bioactives | |
Bhushani et al. | Nanodelivery of nutrients for improved bioavailability | |
Ghiasi et al. | Build-up of a 3D organogel network within the bilayer shell of nanoliposomes. A novel delivery system for vitamin D3: preparation, characterization, and physicochemical stability | |
Assadpour et al. | An overview of lipid-based nanostructures for encapsulation of food ingredients | |
Subroto et al. | Solid lipid nanoparticles: Review of the current research on encapsulation and delivery systems for active and antioxidant compounds | |
Hsieh et al. | A fast and facile platform for fabricating phase-change materials-based drug carriers powered by chemical Marangoni effect | |
WO2020260577A1 (en) | Oil-in-water emulsion of nano-sized self-emulsified particulates | |
JP2023518822A (en) | Pharmaceutical carrier capable of pH-dependent reconstitution, method of production and method of use thereof | |
Chaves et al. | Current applications of liposomes for the delivery of vitamins: a systematic review | |
US20230257653A1 (en) | Fractal formulations | |
Livney | Nanoencapsulation technologies | |
Garg et al. | Colloidal systems: an excellent carrier for nutrient delivery | |
Wen et al. | Solid lipid nanoparticles | |
Homroy et al. | Role of encapsulation on the bioavailability of omega‐3 fatty acids | |
KR20140023669A (en) | The water-insoluble ceramide covered with amorphous surfactant | |
GY | ä StS yolunne so|| | |
Agubata | Self-emulsifying formulations: A pharmaceutical review | |
Cholakova et al. | Triglyceride mixtures: Cold-bursting and double emulsion formation | |
Wen et al. | Nanostructured lipid carriers | |
Stefanov et al. | Technological strategies for the preparation of lipid nanoparticles: an updated review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20737374 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20737374 Country of ref document: EP Kind code of ref document: A1 |